17. Literaturverzeichnis – Follikuläres Lymphom

1. Guideline of the DGGG, DGU and DGRM. S2k-Level, Fertility preservation for patients with malignant disease, AWMF Registry No.015/082, 2017., http://www.awmf.org/leitlinien/detail/ll/015-082.html

2. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Ständige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 1. Auflage 2012. 09.12.2013:

3. Koch-Institut, Robert, Krebs in Deutschland für 2013/2014, 2017.

4. Shiels, Meredith S., Engels, Eric A., Linet, Martha S., Clarke, Christina A., Li, Jianmin, Hall, H. Irene, et.al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2013. 22(6): p. 1069–1078.

5. Morton, Lindsay M., Wang, Sophia S., Devesa, Susan S., Hartge, Patricia, Weisenburger, Dennis D., Linet, Martha S., Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001, Blood, 2006. 107(1): p. 265–276.

6. Robert Koch Institut (2010); Dr. Joachim Bertz, Dr. Stefan Dahm, Dr. Jörg Haberland, Dr. Klaus Kraywinkel, Dr. Bärbel-Maria Kurth, Dr. Ute Wolf, Verbreitung von Krebserkrankungen in Deutschland. Entwicklung der Prävalenzen zwischen 1990 und 2010. Eine Veröffentlichung des Zentrums für Krebsregisterdaten am RKI., 2010.

7. Bosetti, Cristina, Levi, Fabio, Ferlay, Jacques, Lucchini, Franca, Negri, Eva, La Vecchia, Carlo, Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic?, International journal of cancer, 2008. 123(8): p. 1917–1923.

8. Sant, Milena, Minicozzi, Pamela, Mounier, Morgane, Anderson, Lesley A., Brenner, Hermann, Holleczek, Bernd, et.al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study, The Lancet. Oncology, 2014. 15(9): p. 931–942.

9. Pulte, Dianne, Jansen, Lina, Gondos, Adam, Emrich, Katharina, Holleczek, Bernd, Katalinic, Alexander, et.al. Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century, Leukemia & lymphoma, 2013. 54(5): p. 979–985.

10. Herrinton, L. J., Goldoft, M., Schwartz, S. M., Weiss, N. S., The incidence of non-Hodgkin's lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants, Cancer causes & control : CCC, 1996. 7(2): p. 224–230.

11. Morton, Lindsay M., Sampson, Joshua N., Cerhan, James R., Turner, Jennifer J., Vajdic, Claire M., Wang, Sophia S., et.al. Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project, Journal of the National Cancer Institute. Monographs, 2014. 2014(48): p. 1–14.

12. Linet, Martha S., Vajdic, Claire M., Morton, Lindsay M., Roos, Anneclaire J. de, Skibola, Christine F., Boffetta, Paolo, et.al. Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project, Journal of the National Cancer Institute. Monographs, 2014. 2014(48): p. 26–40.

13. Goldin, Lynn R., Björkholm, Magnus, Kristinsson, Sigurdur Y., Turesson, Ingemar, Landgren, Ola, Highly increased familial risks for specific lymphoma subtypes, British journal of haematology, 2009. 146(1): p. 91–94.

14. Brito-Zerón, Pilar, Kostov, Belchin, Fraile, Guadalupe, Caravia-Durán, Daniel, Maure, Brenda, Rascón, Francisco-Javier, et.al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome, Journal of hematology & oncology, 2017. 10(1): p. 90.

15. Castillo, Jorge J., Dalia, Samir, Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies, Leukemia & lymphoma, 2012. 53(10): p. 1911–1919.

16. Diver, W. Ryan, Patel, Alpa V., Thun, Michael J., Teras, Lauren R., Gapstur, Susan M., The association between cigarette smoking and non-Hodgkin lymphoid neoplasms in a large US cohort study, Cancer causes & control : CCC, 2012. 23(8): p. 1231–1240.

17. Parker, A. S., Cerhan, J. R., Dick, F., Kemp, J., Habermann, T. M., Wallace, R. B., et.al. Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older women, Leukemia & lymphoma, 2000. 37(3-4): p. 341–349.

18. Baecklund, Fredrik, Foo, Jia-Nee, Askling, Johan, Eloranta, Sandra, Glimelius, Ingrid, Liu, Jianjun, et.al. Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma, American journal of epidemiology, 2017. 185(8): p. 681–687.

19. Yang, TienYu Owen, Cairns, Benjamin J., Kroll, Mary E., Reeves, Gillian K., Green, Jane, Beral, Valerie, Body size in early life and risk of lymphoid malignancies and histological subtypes in adulthood, International journal of cancer, 2016. 139(1): p. 42–49.

20. Skibola, Christine F., Conde, Lucia, Foo, Jia-Nee, Riby, Jacques, Humphreys, Keith, Sillé, Fenna C. M., et.al. A meta-analysis of genome-wide association studies of follicular lymphoma, BMC genomics, 2012. 13: p. 516.

21. Skibola, Christine F., Berndt, Sonja I., Vijai, Joseph, Conde, Lucia, Wang, Zhaoming, Yeager, Meredith, et.al. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region, American journal of human genetics, 2014. 95(4): p. 462–471.

22. Roulland, Sandrine, Kelly, Rachel S., Morgado, Ester, Sungalee, Stéphanie, Solal-Celigny, Philippe, Colombat, Philippe, et.al. t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. 32(13): p. 1347–1355.

23. Bell, D. A., Liu, Y., Cortopassi, G. A., Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers, Journal of the National Cancer Institute, 1995. 87(3): p. 223–224.

24. Chiu, Brian C-H, Dave, Bhavana J., Blair, Aaron, Gapstur, Susan M., Zahm, Shelia Hoar, Weisenburger, Dennis D., Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma, Blood, 2006. 108(4): p. 1363–1369.

25. Weitmann, Kerstin, Hirt, Carsten, Schwarz, Sabine, Rabkin, Charles, Dölken, Gottfried, Hoffmann, Wolfgang, Influence of reproductive history and exogenous hormone use on prevalence and frequency of circulating t(14;18)-positive cells in a population-based cross-sectional study, Cancer causes & control : CCC, 2015. 26(3): p. 455–465.

26. Hedstrom, L., Graf, L., Stewart, C. B., Rutter, W. J., Phillips, M. A., Modulation of enzyme specificity by site-directed mutagenesis, Methods in enzymology, 1991. 202: p. 671–687.

27. Alavanja, Michael C. R., Hofmann, Jonathan N., Lynch, Charles F., Hines, Cynthia J., Barry, Kathryn H., Barker, Joseph, et.al. Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant use in the agricultural health study, PloS one, 2014. 9(10): p. e109332.

28. Silver, Sharon R., Bertke, Steven J., Hines, Cynthia J., Alavanja, Michael C. R., Hoppin, Jane A., Lubin, Jay H., et.al. Cancer incidence and metolachlor use in the Agricultural Health Study: An update, International journal of cancer, 2015. 137(11): p. 2630–2643.

29. Yang, Jia, Xu, Hong'en, Liang, Xiaodong, Lv, Shiliang, Lin, Baihua, Jia, Yongshi, Allergic conditions are not associated with the risk of non-Hodgkin's lymphoma or Hodgkin's lymphoma: a systematic review and meta-analysis, OncoTargets and therapy, 2017. 10: p. 2189–2198.

30. Psaltopoulou, Theodora, Sergentanis, Theodoros N., Ntanasis-Stathopoulos, Ioannis, Tzanninis, Ioannis-Georgios, Tsilimigras, Diamantis I., Dimopoulos, Meletios A., Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies, International journal of cancer, 2018.

31. Ji, Jianguang, Sundquist, Jan, Sundquist, Kristina, Alcohol consumption has a protective effect against hematological malignancies: a population-based study in Sweden including 420,489 individuals with alcohol use disorders, Neoplasia (New York, N.Y.), 2014. 16(3): p. 229-34, 234.e1.

32. Larfors, Gunnar, Glimelius, Ingrid, Eloranta, Sandra, Smedby, Karin E., Parental Age and Risk of Lymphoid Neoplasms, American journal of epidemiology, 2017. 186(10): p. 1159–1167.

33. Melenotte, Cléa, Million, Matthieu, Audoly, Gilles, Gorse, Audrey, Dutronc, Hervé, Roland, Gauthier, et.al. B-cell non-Hodgkin lymphoma linked to Coxiella burnetii, Blood, 2016. 127(1): p. 113–121.

34. Schmidt, C., Fingerle-Rowson, G., Boehme, A., Brendel, K., Fischer, R., Gonnermann, M., et.al. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009, Leuk Lymphoma, 2015. 56(3): p. 694-702., https://www.ncbi.nlm.nih.gov/pubmed/24937122

35. Kukreti, Vishal, Petersen, Peter, Pintilie, Melania, Tsang, Richard, Crump, Michael, Gospodarowicz, Mary, Extranodal Follicular Lymphoma - a Retrospective Review and Comparison with Localized Nodal Follicular Lymphoma, Blood, 2004. 104(11): p. 1375-1375.

36. Frederiksen, J. K., Sharma, M., Casulo, C., Burack, W. R., Systematic review of the effectiveness of fine-needle aspiration and/or core needle biopsy for subclassifying lymphoma, Arch Pathol Lab Med, 2015. 139(2): p. 245-51., https://www.ncbi.nlm.nih.gov/pubmed/25611108

37. Pugliese, N., Di Perna, M., Cozzolino, I., Ciancia, G., Pettinato, G., Zeppa, P., et.al. Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma, Ann Hematol, 2017. 96(4): p. 627-637., https://www.ncbi.nlm.nih.gov/pubmed/28130574

38. Dong, H. Y., Harris, N. L., Preffer, F. I., Pitman, M. B., Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry, Mod Pathol, 2001. 14(5): p. 472-81., https://www.ncbi.nlm.nih.gov/pubmed/11353059

39. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S, Pileri, S.A., Stein, H., et.al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth EditionIARC, WHO Classification of Tumours, 2008. 2:

40. Johl, A., Lengfelder, E., Hiddemann, W., Klapper, W., German Low-grade Lymphoma Study, Group, Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel, Ann Hematol, 2016. 95(8): p. 1281-6., https://www.ncbi.nlm.nih.gov/pubmed/27236576

41. Strobbe, L., van der Schans, S. A., Heijker, S., Meijer, J. W., Mattijssen, E. J., Mandigers, C. M., et.al. Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry, Leuk Lymphoma, 2014. 55(5): p. 1018-22., https://www.ncbi.nlm.nih.gov/pubmed/23885798

42. Laurent, C., Baron, M., Amara, N., Haioun, C., Dandoit, M., Maynadie, M., et.al. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network, J Clin Oncol, 2017. 35(18): p. 2008-2017., https://www.ncbi.nlm.nih.gov/pubmed/28459613

43. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O., Arranz-Saez, R., et.al. Follicular lymphoma international prognostic index, Blood, 2004. 104(5): p. 1258-65., http://www.ncbi.nlm.nih.gov/pubmed/15126323, http://www.bloodjournal.org/content/bloodjournal/104/5/1258.full.pdf

44. Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., et.al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project, J Clin Oncol, 2009. 27(27): p. 4555-62.

45. Al-Tourah, A. J., Gill, K. K., Chhanabhai, M., Hoskins, P. J., Klasa, R. J., Savage, K. J., et.al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma, J Clin Oncol, 2008. 26(32): p. 5165-9., https://www.ncbi.nlm.nih.gov/pubmed/18838711

46. Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., Tubiana, M., Report of the Committee on Hodgkin's Disease Staging Classification, Cancer Res, 1971. 31(11): p. 1860-1., https://www.ncbi.nlm.nih.gov/pubmed/5121694

47. Stacchini, A., Demurtas, A., Godio, L., Martini, G., Antinoro, V., Palestro, G., Flow cytometry in the bone marrow staging of mature B-cell neoplasms, Cytometry B Clin Cytom, 2003. 54(1): p. 10-8., https://www.ncbi.nlm.nih.gov/pubmed/12827663

48. Schmidt, B., Kremer, M., Gotze, K., John, K., Peschel, C., Hofler, H., et.al. Bone marrow involvement in follicular lymphoma: comparison of histology and flow cytometry as staging procedures, Leuk Lymphoma, 2006. 47(9): p. 1857-62., https://www.ncbi.nlm.nih.gov/pubmed/17064998

49. Iancu, D., Hao, S., Lin, P., Anderson, S. K., Jorgensen, J. L., McLaughlin, P., et.al. Follicular lymphoma in staging bone marrow specimens: correlation of histologic findings with the results of flow cytometry immunophenotypic analysis, Arch Pathol Lab Med, 2007. 131(2): p. 282-7., https://www.ncbi.nlm.nih.gov/pubmed/17284114

50. Merli, M., Arcaini, L., Boveri, E., Rattotti, S., Picone, C., Passamonti, F., et.al. Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry, Eur J Haematol, 2010. 85(5): p. 405-15., https://www.ncbi.nlm.nih.gov/pubmed/20662897

51. Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., et.al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 2014. 32(27): p. 3059-68.

52. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et.al. WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th EditionInternational Agency for Research on Cancer, WHO Classification of Tumours, 2017. 2:

53. Senff, N. J., Noordijk, E. M., Kim, Y. H., Bagot, M., Berti, E., Cerroni, L., et.al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas, Blood, 2008. 112(5): p. 1600-9., https://www.ncbi.nlm.nih.gov/pubmed/18567836

54. Dippel, E., Assaf, C., Becker, J. C., von Bergwelt-Baildon, M., Beyer, M., Cozzio, A., et.al. S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86), J Dtsch Dermatol Ges, 2017. 15(12): p. 1266-1273., https://www.ncbi.nlm.nih.gov/pubmed/29228489

55. Fischer, T., Zing, N. P. C., Chiattone, C. S., Federico, M., Luminari, S., Transformed follicular lymphoma, Ann Hematol, 2018. 97(1): p. 17-29., https://www.ncbi.nlm.nih.gov/pubmed/29043381

56. Bodet-Milin, C., Kraeber-Bodere, F., Moreau, P., Campion, L., Dupas, B., Le Gouill, S., Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma, Haematologica, 2008. 93(3): p. 471-2.

57. Karam, M., Novak, L., Cyriac, J., Ali, A., Nazeer, T., Nugent, F., Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas, Cancer, 2006. 107(1): p. 175-83., https://www.ncbi.nlm.nih.gov/pubmed/16721817

58. Noy, A., Schoder, H., Gonen, M., Weissler, M., Ertelt, K., Cohler, C., et.al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL), Ann Oncol, 2009. 20(3): p. 508-12., https://www.ncbi.nlm.nih.gov/pubmed/19139176

59. Schoder, H., Noy, A., Gonen, M., Weng, L., Green, D., Erdi, Y. E., et.al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma, J Clin Oncol, 2005. 23(21): p. 4643-51., http://www.ncbi.nlm.nih.gov/pubmed/15837966

60. Weiler-Sagie, M., Bushelev, O., Epelbaum, R., Dann, E. J., Haim, N., Avivi, I., et.al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients, J Nucl Med, 2010. 51(1): p. 25-30.

61. Luminari, S., Biasoli, I., Versari, A., Rattotti, S., Bottelli, C., Rusconi, C., et.al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL), Ann Oncol, 2014. 25(2): p. 442-7., http://annonc.oxfordjournals.org/content/25/2/442.full.pdf

62. Decoster, L., Van Puyvelde, K., Mohile, S., Wedding, U., Basso, U., Colloca, G., et.al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger, Ann Oncol, 2015. 26(2): p. 288-300., https://www.ncbi.nlm.nih.gov/pubmed/24936581

63. Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., et.al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol, 2014. 32(24): p. 2595-603., https://www.ncbi.nlm.nih.gov/pubmed/25071125

64. Magnuson, A., Allore, H., Cohen, H. J., Mohile, S. G., Williams, G. R., Chapman, A., et.al. Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research, J Geriatr Oncol, 2016. 7(4): p. 242-8., https://www.ncbi.nlm.nih.gov/pubmed/27197915

65. Jolly, T. A., Deal, A. M., Nyrop, K. A., Williams, G. R., Pergolotti, M., Wood, W. A., et.al. Geriatric assessment-identified deficits in older cancer patients with normal performance status, Oncologist, 2015. 20(4): p. 379-85., https://www.ncbi.nlm.nih.gov/pubmed/25765876

66. Hurria, A., Mohile, S., Gajra, A., Klepin, H., Muss, H., Chapman, A., et.al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer, J Clin Oncol, 2016. 34(20): p. 2366-71., https://www.ncbi.nlm.nih.gov/pubmed/27185838

67. Lee, S. J., Lindquist, K., Segal, M. R., Covinsky, K. E., Development and validation of a prognostic index for 4-year mortality in older adults, JAMA, 2006. 295(7): p. 801-8., https://www.ncbi.nlm.nih.gov/pubmed/16478903

68. Hamaker, M. E., Prins, M. C., Stauder, R., The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review, Leuk Res, 2014. 38(3): p. 275-83., https://www.ncbi.nlm.nih.gov/pubmed/24439052

69. Hamaker, M. E., Schiphorst, A. H., ten Bokkel Huinink, D., Schaar, C., van Munster, B. C., The effect of a geriatric evaluation on treatment decisions for older cancer patients--a systematic review, Acta Oncol, 2014. 53(3): p. 289-96., https://www.ncbi.nlm.nih.gov/pubmed/24134505

70. Nooka, A. K., Nabhan, C., Zhou, X., Taylor, M. D., Byrtek, M., Miller, T. P., et.al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices, Ann Oncol, 2013. 24(2): p. 441-8., https://www.ncbi.nlm.nih.gov/pubmed/23041589

71. Press, O. W., Unger, J. M., Rimsza, L. M., Friedberg, J. W., LeBlanc, M., Czuczman, M. S., et.al. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab, Clin Cancer Res, 2013. 19(23): p. 6624-32., https://www.ncbi.nlm.nih.gov/pubmed/24130072

72. Bachy, E., Maurer, M. J., Habermann, T. M., Gelas-Dore, B., Maucort-Boulch, D., Estell, J. A., et.al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy, Blood, 2018. 132(1): p. 49-58., https://www.ncbi.nlm.nih.gov/pubmed/29666118

73. Casulo, C., Prognostic factors in follicular lymphoma: new tools to personalize risk, Hematology Am Soc Hematol Educ Program, 2016. 2016(1): p. 269-276., https://www.ncbi.nlm.nih.gov/pubmed/27913491

74. Kridel, R., Sehn, L. H., Gascoyne, R. D., Can histologic transformation of follicular lymphoma be predicted and prevented?, Blood, 2017. 130(3): p. 258-266., https://www.ncbi.nlm.nih.gov/pubmed/28408460

75. Fend, F., Quintanilla-Martinez, L., Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma, Haematologica, 2014. 99(4): p. 599-602., https://www.ncbi.nlm.nih.gov/pubmed/24688106

76. Weigert, O., Weinstock, D. M., The promises and challenges of using gene mutations for patient stratification in follicular lymphoma, Blood, 2017. 130(13): p. 1491-1498., https://www.ncbi.nlm.nih.gov/pubmed/28784599

77. Pastore, A., Jurinovic, V., Kridel, R., Hoster, E., Staiger, A. M., Szczepanowski, M., et.al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, Lancet Oncol, 2015. 16(9): p. 1111-1122., https://www.ncbi.nlm.nih.gov/pubmed/26256760

78. Ballman, K. V., Biomarker: Predictive or Prognostic?, J Clin Oncol, 2015. 33(33): p. 3968-71., https://www.ncbi.nlm.nih.gov/pubmed/26392104

79. Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J. A., Zhuang, H., et.al. Utility of FDG-PET scanning in lymphoma by WHO classification, Blood, 2003. 101(10): p. 3875-6.

80. Wirth, A., Foo, M., Seymour, J. F., Macmanus, M. P., Hicks, R. J., Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma, Int J Radiat Oncol Biol Phys, 2008. 71(1): p. 213-9., http://www.ncbi.nlm.nih.gov/pubmed/18295982

81. Fueger, B. J., Yeom, K., Czernin, J., Sayre, J. W., Phelps, M. E., Allen-Auerbach, M. S., Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma, Mol Imaging Biol, 2009. 11(4): p. 269-74.

82. Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S. P., et.al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group, J Clin Oncol, 2014. 32(27): p. 3048-58., http://www.ncbi.nlm.nih.gov/pubmed/25113771, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015423/pdf/zlj3048.pdf

83. Luminari, S., Biasoli, I., Arcaini, L., Versari, A., Rusconi, C., Merli, F., et.al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi, Ann Oncol, 2013. 24(8): p. 2108-12.

84. Chen, Y. K., Yeh, C. L., Tsui, C. C., Liang, J. A., Chen, J. H., Kao, C. H., F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis, Clin Nucl Med, 2011. 36(7): p. 553-9., http://ssr-eus-go-csi.cloudapp.net/v1/assets?wkmrid=JOURNAL%2Fcnum%2Fbeta%2F00003072-201107000-00009%2Froot%2Fv%2F2017-05-23T190901Z%2Fr%2Fapplication-pdf

85. Cho, S. F., Chang, C. C., Liu, Y. C., Chang, C. S., Hsiao, H. H., Liu, T. C., et.al. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma, Kaohsiung J Med Sci, 2015. 31(3): p. 130-7., http://www.ncbi.nlm.nih.gov/pubmed/25744235

86. Ngeow, J. Y., Quek, R. H., Ng, D. C., Hee, S. W., Tao, M., Lim, L. C., et.al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma, Ann Oncol, 2009. 20(9): p. 1543-7.

87. Ujjani, C. S., Hill, E. M., Wang, H., Nassif, S., Esposito, G., Ozdemirli, M., et.al. (18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma, British Journal of Haematology, 2016. 174(3): p. 410-6.

88. Adams, H. J., Kwee, T. C., Fijnheer, R., Dubois, S. V., Blase, P. E., Nievelstein, R. A., et.al. Utility of quantitative FDG-PET/CT for the detection of bone marrow involvement in follicular lymphoma: a histopathological correlation study, Skeletal Radiol, 2014. 43(9): p. 1231-6., https://link.springer.com/content/pdf/10.1007%2Fs00256-014-1919-1.pdf

89. Perry, C., Lerman, H., Joffe, E., Sarid, N., Amit, O., Avivi, I., et.al. The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma, Medicine (Baltimore), 2016. 95(9): p. e2910., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782871/pdf/medi-95-e2910.pdf

90. Le Dortz, L., De Guibert, S., Bayat, S., Devillers, A., Houot, R., Rolland, Y., et.al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma, Eur J Nucl Med Mol Imaging, 2010. 37(12): p. 2307-14., https://www.ncbi.nlm.nih.gov/pubmed/20717826

91. Janikova, A., Bolcak, K., Pavlik, T., Mayer, J., Kral, Z., Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?, Clin Lymphoma Myeloma, 2008. 8(5): p. 287-93., https://www.ncbi.nlm.nih.gov/pubmed/18854283

92. Metser, U., Dudebout, J., Baetz, T., Hodgson, D. C., Langer, D. L., MacCrostie, P., et.al. [(18) F]-FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study, Cancer, 2017. 123(15): p. 2860-2866.

93. Meignan, M., Cottereau, A. S., Versari, A., Chartier, L., Dupuis, J., Boussetta, S., et.al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies, J Clin Oncol, 2016., http://www.ncbi.nlm.nih.gov/pubmed/27551111

94. Trotman, J., Fournier, M., Lamy, T., Seymour, J. F., Sonet, A., Janikova, A., et.al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants, Journal of Clinical Oncology, 2011. 29(23): p. 3194-200.

95. Dupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., et.al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS, J Clin Oncol, 2012. 30(35): p. 4317-22., http://www.ncbi.nlm.nih.gov/pubmed/23109699

96. Adams, H. J., Nievelstein, R. A., Kwee, T. C., Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review, Ann Hematol, 2016. 95(1): p. 11-8., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700102/pdf/277_2015_Article_2553.pdf

97. Lu, Z., Lin, M., Downe, P., Chong, S., Ling, S., The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma, Ann Nucl Med, 2014. 28(8): p. 805-11., http://www.ncbi.nlm.nih.gov/pubmed/25008291, https://link.springer.com/content/pdf/10.1007%2Fs12149-014-0874-1.pdf

98. Bishu, S., Quigley, J. M., Bishu, S. R., Olsasky, S. M., Stem, R. A., Shostrom, V. K., et.al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma, Leuk Lymphoma, 2007. 48(8): p. 1548-55., http://www.ncbi.nlm.nih.gov/pubmed/17701586, http://www.tandfonline.com/doi/pdf/10.1080/10428190701422059?needAccess=true

99. Pyo, J., Won Kim, K., Jacene, H. A., Sakellis, C. G., Brown, J. R., Van den Abbeele, A. D., End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis, Clinical Cancer Research, 2013. 19(23): p. 6566-77.

100. Wong-Sefidan, I., Byrtek, M., Zhou, X., Friedberg, J. W., Flowers, C. R., Zelenetz, A. D., et.al. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice, Leuk Lymphoma, 2016. p. 1-7., http://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1213824?needAccess=true

101. Trotman, J., Luminari, S., Boussetta, S., Versari, A., Dupuis, J., Tychyj, C., et.al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.[Erratum appears in Lancet Haematol. 2014 Oct;1(1):e16; PMID: 27030063], The Lancet Haematology, 2014. 1(1): p. e17-27., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=27030064

102. Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, et al., Prognostic value of end of induction PET response after first-line immunochemotherapy for follicular lymphoma in the randomised, open-label, phase 3 GALLIUM study, Lancet Oncol (in press), 2018.

103. Gomez Leon, N., Delgado-Bolton, R. C., Del Campo Del Val, L., Cabezas, B., Arranz, R., Garcia, M., et.al. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma, Clin Nucl Med, 2017., http://ssr-eus-go-csi.cloudapp.net/v1/assets?wkmrid=JOURNAL%2Fcnum%2Fbeta%2F00003072-201708000-00004%2Froot%2Fv%2F2017-06-29T084432Z%2Fr%2Fapplication-pdf

104. Kostakoglu, L., Goy, A., Martinelli, G., Caballero, D., Crump, M., Gaidano, G., et.al. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study, Leuk Lymphoma, 2016. p. 1-10., http://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1196815?needAccess=true

105. Lopci, E., Zanoni, L., Chiti, A., Fonti, C., Santi, I., Zinzani, P. L., et.al. FDG PET/CT predictive role in follicular lymphoma, Eur J Nucl Med Mol Imaging, 2012. 39(5): p. 864-71.

106. Ulaner, G. A., Lilienstein, J., Gonen, M., Maragulia, J., Moskowitz, C. H., Zelenetz, A. D., False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma, J Clin Oncol, 2014. 32(1): p. 51-6.

107. Pott, C., Bruggemann, M., Ritgen, M., van der Velden, V. H., van Dongen, J. J., Kneba, M., MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR, Methods Mol Biol, 2013. 971: p. 175-200., https://www.ncbi.nlm.nih.gov/pubmed/23296964

108. Lobetti-Bodoni, C., Mantoan, B., Monitillo, L., Genuardi, E., Drandi, D., Barbero, D., et.al. Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma, Ther Adv Hematol, 2013. 4(3): p. 189-98., https://www.ncbi.nlm.nih.gov/pubmed/23730496

109. van der Velden, V. H., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E. R., et.al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data, Leukemia, 2007. 21(4): p. 604-11., https://www.ncbi.nlm.nih.gov/pubmed/17287850

110. Painter, D., Smith, A., de Tute, R., Crouch, S., Roman, E., Jack, A., The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients, Br J Haematol, 2015. 170(2): p. 175-8., https://www.ncbi.nlm.nih.gov/pubmed/25920510

111. Rambaldi, A., Carlotti, E., Oldani, E., Della Starza, I., Baccarani, M., Cortelazzo, S., et.al. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma, Blood, 2005. 105(9): p. 3428-33., https://www.ncbi.nlm.nih.gov/pubmed/15637137

112. Zohren, F., Bruns, I., Pechtel, S., Schroeder, T., Fenk, R., Czibere, A., et.al. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy, Blood, 2015. 126(12): p. 1407-14.

113. Pulsoni, A., Starza, I. D., Frattarelli, N., Ghia, E., Carlotti, E., Cavalieri, E., et.al. Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy, Br J Haematol, 2007. 137(3): p. 216-20., https://www.ncbi.nlm.nih.gov/pubmed/17408460

114. Herfarth, K., Borchmann, P., Schnaidt, S., Hohloch, K., Budach, Volker; Engelhard, Marianne; Viardot, Andreas; Engenhart-Cabillic, Rita; Keller, Ulrich; Reinartz, Gabriele; Eich, Hans-Theodor; Witzens-Harig, Mathias; Hess, Clemens; Dörken, Bernd; Dürig, Jan; Wiegel, Thomas; Hiddemann, Wolfgang; Hoster, Eva1; Pott, Christiane; Dreyling, Martin, Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma, HemaSphere, 2018. 2(6):

115. Pott, Christiane, Hoster, Eva, Kehden, Britta, Unterhalt, Michael, Herold, Michael, van der Jagt, Richard H, et.al. Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study, Blood, 2016. 128(22): p. 613-613.

116. Galimberti, S., Luminari, S., Ciabatti, E., Grassi, S., Guerrini, F., Dondi, A., et.al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial, Clin Cancer Res, 2014. 20(24): p. 6398-405., https://www.ncbi.nlm.nih.gov/pubmed/25316810

117. Hirt, C., Schuler, F., Kiefer, T., Schwenke, C., Haas, A., Niederwieser, D., et.al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients, Br J Haematol, 2008. 141(5): p. 631-40., https://www.ncbi.nlm.nih.gov/pubmed/18422779

118. Pott, Christiane, Hoster, Eva, Kehden, Britta, Unterhalt, Michael, Herold, Michael, van der Jagt, Richard, et.al. Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients, Blood, 2018. 132(Suppl 1): p. 396-396.

119. Ladetto, M., De Marco, F., Benedetti, F., Vitolo, U., Patti, C., Rambaldi, A., et.al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage, Blood, 2008. 111(8): p. 4004-13., https://www.ncbi.nlm.nih.gov/pubmed/18239086

120. Ladetto, M., Lobetti-Bodoni, C., Mantoan, B., Ceccarelli, M., Boccomini, C., Genuardi, E., et.al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program, Blood, 2013. 122(23): p. 3759-66., https://www.ncbi.nlm.nih.gov/pubmed/24085766

121. Pott, Christiane, Belada, David, Danesi, Nathalie, Fingerle-Rowson, Günter, Gribben, John, Harbron, Chris, et.al. Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma, Blood, 2015. 126(23): p. 3978-3978.

122. Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haioun, C., Moreau, P., et.al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte, J Clin Oncol, 1997. 15(3): p. 1110-7., https://www.ncbi.nlm.nih.gov/pubmed/9060552

123. Setting, Institute of Medicine Committee on Psychosocial Services to Cancer Patients/Families in a Community, The National Academies Collection: Reports funded by National Institutes of Health, in Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs, Adler, N. E. and Page, A. E. K., Editors. 2008, National Academies Press (US): Washington (DC).

124. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1.1, 2014, AWMF-Registernummer: 032/051OL, 2014., http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html

125. Kusch, M., Labouvie, H., Hein-Nau, B., Schwarzkamp, U., Wolf, J., Hallek, M., [Integrated psychooncology: implementation of psychooncological health care at the Center for Integrated Oncology Cologne - Bonn], Dtsch Med Wochenschr, 2014. 139(46): p. 2357-60., https://www.ncbi.nlm.nih.gov/pubmed/25369048

126. Kusch, Michael, Labouvie, Hildegard, Hein-Nau, Birgitt, Klinische PsychoonkologieSpringer, 2013.

127. Pirl, W. F., Fann, J. R., Greer, J. A., Braun, I., Deshields, T., Fulcher, C., et.al. Recommendations for the implementation of distress screening programs in cancer centers: report from the American Psychosocial Oncology Society (APOS), Association of Oncology Social Work (AOSW), and Oncology Nursing Society (ONS) joint task force, Cancer, 2014. 120(19): p. 2946-54., https://www.ncbi.nlm.nih.gov/pubmed/24798107

128. Donovan, K. A., Grassi, L., McGinty, H. L., Jacobsen, P. B., Validation of the distress thermometer worldwide: state of the science, Psychooncology, 2014. 23(3): p. 241-50., https://www.ncbi.nlm.nih.gov/pubmed/25160838

129. Andersen, B. L., DeRubeis, R. J., Berman, B. S., Gruman, J., Champion, V. L., Massie, M. J., et.al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation, J Clin Oncol, 2014. 32(15): p. 1605-19., https://www.ncbi.nlm.nih.gov/pubmed/24733793

130. Herrmann, C., Buss, U., Snaith, R.P, Zigmond, AS, HADS-D: Hospital Anxiety and Depression Scale – Deutsche Version. Testdokumentation und Handanweisung1993, Huber: Bern.

131. Holland, JC, Breitbart, WS, Jacobsen, PB, Lederbarg, MS, Loscalzo, MJ, MccorKle, RS, Psycho-Oncology 2nd EditionOxford University Press, 2010.

132. Brintzenhofe-Szoc, K. M., Levin, T. T., Li, Y., Kissane, D. W., Zabora, J. R., Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type, Psychosomatics, 2009. 50(4): p. 383-91., https://www.ncbi.nlm.nih.gov/pubmed/19687179

133. Mitchell, A. J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., et.al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies, Lancet Oncol, 2011. 12(2): p. 160-74., https://www.ncbi.nlm.nih.gov/pubmed/21251875

134. Wise, TN, Biondi, M, Costantini, A, Psycho-OncologyAmerican Psychiatric Publishing, 2013.

135. Holland, Jimmie C., Weiss, Talia R., History of psycho-oncology, in Psycho-oncology, 2nd ed., 2010, Oxford University Press: New York, NY, US. p. 3-12.

136. Oerlemans, S., Mols, F., Nijziel, M. R., Zijlstra, W. P., Coebergh, J. W., van de Poll-Franse, L. V., The course of anxiety and depression for patients with Hodgkin's lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry, J Cancer Surviv, 2014. 8(4): p. 555-64., https://www.ncbi.nlm.nih.gov/pubmed/24820429

137. Gascon, P., Arranz, R., Bargay, J., Ramos, F., Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma, Support Care Cancer, 2018. 26(4): p. 1253-1264., https://www.ncbi.nlm.nih.gov/pubmed/29116407

138. Paradisi, R., Vicenti, R., Macciocca, M., Seracchioli, R., Rossi, S., Fabbri, R., High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma, Fertil Steril, 2016. 106(5): p. 1176-1182., https://www.ncbi.nlm.nih.gov/pubmed/27430206

139. Lawrenz, B., Fehm, T., von Wolff, M., Soekler, M., Huebner, S., Henes, J., et.al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma--evaluation by using antimullerian hormone and retrieved oocytes, Fertil Steril, 2012. 98(1): p. 141-4., https://www.ncbi.nlm.nih.gov/pubmed/22607891

140. van der Kaaij, M. A., Heutte, N., van Echten-Arends, J., Raemaekers, J. M., Carde, P., Noordijk, E. M., et.al. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials, Haematologica, 2009. 94(12): p. 1691-7., https://www.ncbi.nlm.nih.gov/pubmed/19850901

141. Bahadur, G., Ozturk, O., Muneer, A., Wafa, R., Ashraf, A., Jaman, N., et.al. Semen quality before and after gonadotoxic treatment, Hum Reprod, 2005. 20(3): p. 774-81., https://www.ncbi.nlm.nih.gov/pubmed/15689346

142. Wallace, W. H., Thomson, A. B., Kelsey, T. W., The radiosensitivity of the human oocyte, Hum Reprod, 2003. 18(1): p. 117-21., https://www.ncbi.nlm.nih.gov/pubmed/12525451

143. Teh, W. T., Stern, C., Chander, S., Hickey, M., The impact of uterine radiation on subsequent fertility and pregnancy outcomes, Biomed Res Int, 2014. 2014: p. 482968., https://www.ncbi.nlm.nih.gov/pubmed/25165706

144. Lambertini, M., Del Mastro, L., Pescio, M. C., Andersen, C. Y., Azim, H. A., Jr., Peccatori, F. A., et.al. Cancer and fertility preservation: international recommendations from an expert meeting, BMC Med, 2016. 14: p. 1., https://www.ncbi.nlm.nih.gov/pubmed/26728489

145. Hwang, S., Lee, S. G., Ha, T. Y., Ahn, C. S., Park, K. M., Kim, K. H., et.al. Feasibility assessment for tailoring preservation of segment VIII hepatic vein during left liver graft procurement, Hepatogastroenterology, 2006. 53(72): p. 928-32., https://www.ncbi.nlm.nih.gov/pubmed/17153455

146. Elis, A., Tevet, A., Yerushalmi, R., Blickstein, D., Bairy, O., Dann, E. J., et.al. Fertility status among women treated for aggressive non-Hodgkin's lymphoma, Leuk Lymphoma, 2006. 47(4): p. 623-7., https://www.ncbi.nlm.nih.gov/pubmed/16690520

147. Meirow, D., Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers, Leuk Lymphoma, 1999. 33(1-2): p. 65-76., https://www.ncbi.nlm.nih.gov/pubmed/10194122

148. Franchi-Rezgui, P., Rousselot, P., Espie, M., Briere, J., Pierre Marolleau, J., Gisselbrecht, C., et.al. Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas, Hematol J, 2003. 4(2): p. 116-20., https://www.ncbi.nlm.nih.gov/pubmed/12750730

149. Meissner, J., Tichy, D., Dietrich, S., Schmitt, T., Ziepert, M., Kuhnt, E., et.al. Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma, Br J Haematol, 2014. 166(4): p. 612-5., https://www.ncbi.nlm.nih.gov/pubmed/24689462

150. Meissner, J., Tichy, D., Katzke, V., Kuhn, T., Dietrich, S., Schmitt, T., et.al. Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma, Ann Oncol, 2015. 26(8): p. 1771-6., https://www.ncbi.nlm.nih.gov/pubmed/25962442

151. Muller, U., Stahel, R. A., Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma, Ann Oncol, 1993. 4(5): p. 399-402., https://www.ncbi.nlm.nih.gov/pubmed/7688980

152. Bokemeyer, C., Schmoll, H. J., van Rhee, J., Kuczyk, M., Schuppert, F., Poliwoda, H., Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma, Ann Hematol, 1994. 68(3): p. 105-10., https://www.ncbi.nlm.nih.gov/pubmed/8167175

153. Meistrich, M. L., Effects of chemotherapy and radiotherapy on spermatogenesis in humans, Fertil Steril, 2013. 100(5): p. 1180-6.

154. Jahnukainen, K., Ehmcke, J., Hou, M., Schlatt, S., Testicular function and fertility preservation in male cancer patients, Best Pract Res Clin Endocrinol Metab, 2011. 25(2): p. 287-302.

155. Silber, S. J., The use of epididymal sperm for the treatment of male infertility, Baillieres Clin Obstet Gynaecol, 1997. 11(4): p. 739-52.

156. Meistrich, M. L., Wilson, G., Mathur, K., Fuller, L. M., Rodriguez, M. A., McLaughlin, P., et.al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease, J Clin Oncol, 1997. 15(12): p. 3488-95.

157. Choy, J. T., Brannigan, R. E., The determination of reproductive safety in men during and after cancer treatment, Fertil Steril, 2013. 100(5): p. 1187-91.

158. Chatterjee, R., Haines, G. A., Perera, D. M., Goldstone, A., Morris, I. D., Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia, Hum Reprod, 2000. 15(4): p. 762-6., https://www.ncbi.nlm.nih.gov/pubmed/10739816

159. Byrne, P. A., Health care decisions, Linacre Q, 1998. 65(3): p. 52-8.

160. Schuring, A. N., Fehm, T., Behringer, K., Goeckenjan, M., Wimberger, P., Henes, M., et.al. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation, Arch Gynecol Obstet, 2018. 297(1): p. 241-255., https://www.ncbi.nlm.nih.gov/pubmed/29177593

161. Dittrich, R., Kliesch, S., Schuring, A., Balcerek, M., Baston-Bust, D. M., Beck, R., et.al. Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) - Recommendations and Statements for Girls and Women, Geburtshilfe Frauenheilkd, 2018. 78(6): p. 567-584., https://www.ncbi.nlm.nih.gov/pubmed/29962516

162. von Wolff, M., Germeyer, A., Liebenthron, J., Korell, M., Nawroth, F., Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques, Arch Gynecol Obstet, 2018. 297(1): p. 257-267., https://www.ncbi.nlm.nih.gov/pubmed/29181578

163. Kliesch, S., Behre, H. M., Jurgens, H., Nieschlag, E., Cryopreservation of semen from adolescent patients with malignancies, Med Pediatr Oncol, 1996. 26(1): p. 20-7.

164. Kamischke, A., Jurgens, H., Hertle, L., Berdel, W. E., Nieschlag, E., Cryopreservation of sperm from adolescents and adults with malignancies, J Androl, 2004. 25(4): p. 586-92.

165. Daudin, Myriam, Rives, Nathalie, Walschaerts, Marie, Drouineaud, Véronique, Szerman, Ethel, Koscinski, Isabelle, et.al. Sperm cryopreservation in adolescents and young adults with cancer: results of the French national sperm banking network (CECOS), Fertility and Sterility 103(2): p. 478-486.e1., http://dx.doi.org/10.1016/j.fertnstert.2014.11.012

166. Colpi, G. M., Colpi, E. M., Piediferro, G., Giacchetta, D., Gazzano, G., Castiglioni, F. M., et.al. Microsurgical TESE versus conventional TESE for ICSI in non-obstructive azoospermia: a randomized controlled study, Reprod Biomed Online, 2009. 18(3): p. 315-9.

167. Kliesch, Sabine, Kamischke, Axel, Cooper, Trevor G., Nieschlag, Eberhard, Kryokonservierung menschlicher Spermien zur Zeugungsreserve, in Andrologie: Grundlagen und Klinik der reproduktiven Gesundheit des Mannes, Nieschlag, EberhardBehre, Hermann M. and Nieschlag, Susan, Editors. 2009, Springer Berlin Heidelberg: Berlin, Heidelberg. p. 515-531., http://dx.doi.org/10.1007/978-3-540-92963-5_24

168. Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., et.al. Guidelines on Testicular Cancer: 2015 Update, Eur Urol, 2015. 68(6): p. 1054-68., http://www.ncbi.nlm.nih.gov/pubmed/26297604

169. MacManus, M., Fisher, R., Roos, D., O'Brien, P., Macann, A., Davis, S., et.al. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03, J Clin Oncol, 2018. p. JCO2018779892., https://www.ncbi.nlm.nih.gov/pubmed/29975623

170. Ruella, M., Filippi, A. R., Bruna, R., Di Russo, A., Magni, M., Caracciolo, D., et.al. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study, Int J Radiat Oncol Biol Phys, 2016. 94(4): p. 783-91., https://www.ncbi.nlm.nih.gov/pubmed/26972651

171. Advani, R., Rosenberg, S. A., Horning, S. J., Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy, J Clin Oncol, 2004. 22(8): p. 1454-9., https://www.ncbi.nlm.nih.gov/pubmed/15024027

172. Vargo, J. A., Gill, B. S., Balasubramani, G. K., Beriwal, S., What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?, Cancer, 2015. 121(18): p. 3325-34., https://www.ncbi.nlm.nih.gov/pubmed/26042364

173. Friedberg, J. W., Byrtek, M., Link, B. K., Flowers, C., Taylor, M., Hainsworth, J., et.al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study, J Clin Oncol, 2012. 30(27): p. 3368-75., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675665/pdf/zlj3368.pdf

174. Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., et.al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial, Radiother Oncol, 2011. 100(1): p. 86-92., https://www.ncbi.nlm.nih.gov/pubmed/21664710

175. M. Engelhard, M. Unterhalt, M. Hansmann, M. Stuschke, Follicular Lymphoma: Curability By Radiotherapy In Limited Stage Nodal Disease? Updated Results Of a Randomized Trial., Annals of Oncology, 2011. 22(suppl_4): p. iv90-iv91., http://dx.doi.org/10.1093/annonc/mdr189

176. Mac Manus, M. P., Hoppe, R. T., Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University, J Clin Oncol, 1996. 14(4): p. 1282-90., https://www.ncbi.nlm.nih.gov/pubmed/8648385

177. Engelhard, M., M. Unterhalt, M. L. Hansmann and M. Stuschke, Follicular lymphoma: Final results of the randomized evaluation of curative radiotherapy in limited stage nodal diseaseStrahlentherapie und Onkologie, 2013. Volume 189, Supplement 1:

178. Witzens-Harig, M., Hensel, M., Unterhalt, M., Herfarth, K., Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial, BMC Cancer, 2011. 11: p. 87., https://www.ncbi.nlm.nih.gov/pubmed/21352561

179. Illidge, T., Specht, L., Yahalom, J., Aleman, B., Berthelsen, A. K., Constine, L., et.al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group, Int J Radiat Oncol Biol Phys, 2014. 89(1): p. 49-58., https://www.ncbi.nlm.nih.gov/pubmed/24725689

180. Stuschke, M., Hoederath, A., Sack, H., Potter, R., Muller, R. P., Schulz, U., et.al. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fruhe Stadien, Cancer, 1997. 80(12): p. 2273-84., https://www.ncbi.nlm.nih.gov/pubmed/9404705

181. Hoskin, P. J., Kirkwood, A. A., Popova, B., Smith, P., Robinson, M., Gallop-Evans, E., et.al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial, Lancet Oncol, 2014. 15(4): p. 457-63., https://www.ncbi.nlm.nih.gov/pubmed/24572077

182. Herfarth, K., Konig, L., [Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study], Strahlenther Onkol, 2014. 190(11): p. 1084-5., https://www.ncbi.nlm.nih.gov/pubmed/25538992

183. Ardeshna, K. M., Smith, P., Norton, A., Hancock, B. W., Hoskin, P. J., MacLennan, K. A., et.al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial, Lancet, 2003. 362(9383): p. 516-22., https://www.ncbi.nlm.nih.gov/pubmed/12932382

184. Ardeshna, K. M., Qian, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., et.al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial, Lancet Oncol, 2014. 15(4): p. 424-35., https://www.ncbi.nlm.nih.gov/pubmed/24602760

185. Martinelli, G., Schmitz, S. F., Utiger, U., Cerny, T., Hess, U., Bassi, S., et.al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98, J Clin Oncol, 2010. 28(29): p. 4480-4., https://www.ncbi.nlm.nih.gov/pubmed/20697092

186. Nastoupil, L. J., Sinha, R., Byrtek, M., Ziemiecki, R., Zhou, X., Taylor, M., et.al. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era, Br J Haematol, 2016. 172(5): p. 724-34., https://www.ncbi.nlm.nih.gov/pubmed/26729445

187. Colombat, P., Brousse, N., Salles, G., Morschhauser, F., Brice, P., Soubeyran, P., et.al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up, Ann Oncol, 2012. 23(9): p. 2380-5., https://www.ncbi.nlm.nih.gov/pubmed/22782332

188. Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Vitolo, U., Ladetto, M., Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2016. 27(suppl 5): p. v83-v90.

189. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., et.al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, 2005. 106(12): p. 3725-32., https://www.ncbi.nlm.nih.gov/pubmed/16123223

190. Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K. H., Neubauer, A., et.al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study, J Clin Oncol, 2007. 25(15): p. 1986-92., https://www.ncbi.nlm.nih.gov/pubmed/17420513

191. Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., et.al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma, J Clin Oncol, 2008. 26(28): p. 4579-86., https://www.ncbi.nlm.nih.gov/pubmed/18662969

192. Salles, G., Mounier, N., de Guibert, S., Morschhauser, F., Doyen, C., Rossi, J. F., et.al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study, Blood, 2008. 112(13): p. 4824-31., https://www.ncbi.nlm.nih.gov/pubmed/18799723

193. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., et.al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 2005. 105(4): p. 1417-23., https://www.ncbi.nlm.nih.gov/pubmed/15494430

194. Karlin, L., Coiffier, B., Ofatumumab in the treatment of non-Hodgkin's lymphomas, Expert Opin Biol Ther, 2015. 15(7): p. 1085-91., https://www.ncbi.nlm.nih.gov/pubmed/26043777

195. Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., et.al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma, N Engl J Med, 2017. 377(14): p. 1331-1344., https://www.ncbi.nlm.nih.gov/pubmed/28976863

196. Launonen, Aino, Hiddemann, Wolfgang, Duenzinger, Ulrich, Fingerle-Rowson, Günter, Nielsen, Tina, Marcus, Robert, Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study, Blood, 2017. 130(Suppl 1): p. 1490-1490.

197. Seymour, J. F., Marcus, R., Davies, A., Gallop-Evans, E., Grigg, A., Haynes, A., et.al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression, Haematologica, 2018., https://www.ncbi.nlm.nih.gov/pubmed/30573503

198. Jurczak, W., Moreira, I., Kanakasetty, G. B., Munhoz, E., Echeveste, M. A., Giri, P., et.al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study, Lancet Haematol, 2017. 4(8): p. e350-e361., https://www.ncbi.nlm.nih.gov/pubmed/28712941

199. Kim, W. S., Buske, C., Ogura, M., Jurczak, W., Sancho, J. M., Zhavrid, E., et.al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial, Lancet Haematol, 2017. 4(8): p. e362-e373., https://www.ncbi.nlm.nih.gov/pubmed/28712940

200. Ogura, M., Sancho, J. M., Cho, S. G., Nakazawa, H., Suzumiya, J., Tumyan, G., et.al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial, Lancet Haematol, 2018. 5(11): p. e543-e553., https://www.ncbi.nlm.nih.gov/pubmed/30389036

201. Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grunhagen, U., Losem, C., et.al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, Lancet, 2013. 381(9873): p. 1203-10., https://www.ncbi.nlm.nih.gov/pubmed/23433739

202. Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., Macdonald, D., et.al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, Blood, 2014. 123(19): p. 2944-52., https://www.ncbi.nlm.nih.gov/pubmed/24591201

203. Grigg, A., Dyer, M. J., Diaz, M. G., Dreyling, M., Rule, S., Lei, G., et.al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma, Haematologica, 2017. 102(4): p. 765-772., https://www.ncbi.nlm.nih.gov/pubmed/28011903

204. Hiddemann, W., Barbui, A. M., Canales, M. A., Cannell, P. K., Collins, G. P., Durig, J., et.al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety, J Clin Oncol, 2018. 36(23): p. 2395-2404., https://www.ncbi.nlm.nih.gov/pubmed/29856692

205. Federico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., et.al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi, J Clin Oncol, 2013. 31(12): p. 1506-13., https://www.ncbi.nlm.nih.gov/pubmed/23530110

206. Luminari, S., Ferrari, A., Manni, M., Dondi, A., Chiarenza, A., Merli, F., et.al. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma, J Clin Oncol, 2018. 36(7): p. 689-696., https://www.ncbi.nlm.nih.gov/pubmed/29095677

207. Ghielmini, M., Rufibach, K., Salles, G., Leoncini-Franscini, L., Leger-Falandry, C., Cogliatti, S., et.al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK), Ann Oncol, 2005. 16(10): p. 1675-82., https://www.ncbi.nlm.nih.gov/pubmed/16030029

208. Kahl, B. S., Hong, F., Williams, M. E., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., et.al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402, J Clin Oncol, 2014. 32(28): p. 3096-102., https://www.ncbi.nlm.nih.gov/pubmed/25154829

209. Taverna, C., Martinelli, G., Hitz, F., Mingrone, W., Pabst, T., Cevreska, L., et.al. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03, J Clin Oncol, 2016. 34(5): p. 495-500., https://www.ncbi.nlm.nih.gov/pubmed/26712227

210. Williams, M. E., Hong, F., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., Habermann, T. M., et.al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402, Br J Haematol, 2016. 173(6): p. 867-75., https://www.ncbi.nlm.nih.gov/pubmed/26970533

211. Fowler, N. H., Davis, R. E., Rawal, S., Nastoupil, L., Hagemeister, F. B., McLaughlin, P., et.al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial, Lancet Oncol, 2014. 15(12): p. 1311-8., https://www.ncbi.nlm.nih.gov/pubmed/25439689

212. Martin, P., Jung, S. H., Pitcher, B., Bartlett, N. L., Blum, K. A., Shea, T., et.al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance), Ann Oncol, 2017. 28(11): p. 2806-2812., https://www.ncbi.nlm.nih.gov/pubmed/28945884

213. Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., et.al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma, N Engl J Med, 2018. 379(10): p. 934-947., https://www.ncbi.nlm.nih.gov/pubmed/30184451

214. Vidal, L., Gafter-Gvili, A., Salles, G., Bousseta, S., Oberman, B., Rubin, C., et.al. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis, Eur J Cancer, 2017. 76: p. 216-225., https://www.ncbi.nlm.nih.gov/pubmed/28336303

215. Salles, G., Seymour, J. F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., et.al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, 2011. 377(9759): p. 42-51., https://www.ncbi.nlm.nih.gov/pubmed/21176949

216. Salles, Gilles Andre, Seymour, John Francis, Feugier, Pierre, Offner, Fritz, Lopez-Guillermo, Armando, Belada, David, et.al. Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years, Blood, 2017. 130(Suppl 1): p. 486-486.

217. Hoster, E., Unterhalt, M., Hänel, M., Prange-Krex, G., Forstpointner, R., Florschütz, A., et.al. RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO, Hematological Oncology, 2017. 35(S2): p. 32-32., https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2437_12

218. Rummel, Mathias J, Buske, Christian, Hertenstein, Bernd, Lerchenmüller, Christian, Koenigsmann, Michael, Lange, Elisabeth, et.al. Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study), Blood, 2017. 130(Suppl 1): p. 483-483.

219. Davies, A., Merli, F., Mihaljevic, B., Mercadal, S., Siritanaratkul, N., Solal-Celigny, P., et.al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial, Lancet Haematol, 2017. 4(6): p. e272-e282., https://www.ncbi.nlm.nih.gov/pubmed/28476440

220. Casulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., et.al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study, J Clin Oncol, 2015. 33(23): p. 2516-22., https://www.ncbi.nlm.nih.gov/pubmed/26124482

221. Rohatiner, A. Z., Gregory, W. M., Peterson, B., Borden, E., Solal-Celigny, P., Hagenbeek, A., et.al. Meta-analysis to evaluate the role of interferon in follicular lymphoma, J Clin Oncol, 2005. 23(10): p. 2215-23., https://www.ncbi.nlm.nih.gov/pubmed/15684317

222. Baldo, P., Rupolo, M., Compagnoni, A., Lazzarini, R., Bearz, A., Cannizzaro, R., et.al. Interferon-alpha for maintenance of follicular lymphoma, Cochrane Database Syst Rev, 2010. p. CD004629., https://www.ncbi.nlm.nih.gov/pubmed/20091564

223. Morschhauser, F., Radford, J., Van Hoof, A., Botto, B., Rohatiner, A. Z., Salles, G., et.al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial, J Clin Oncol, 2013. 31(16): p. 1977-83., https://www.ncbi.nlm.nih.gov/pubmed/23547079

224. Shadman, M., Li, H., Rimsza, L., Leonard, J. P., Kaminski, M. S., Braziel, R. M., et.al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016, J Clin Oncol, 2018. 36(7): p. 697-703., https://www.ncbi.nlm.nih.gov/pubmed/29356608

225. Canales, Miguel A., Dlouhy, Ivan, Briones, Javier, Caballero, Dolores, Sancho, Juan Manuel, Vilchez, Santiago Mercadal, et.al. A Randomized Phase II Study Comparing Consolidation With a Single Dose Of ⁹⁰y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization, Blood, 2013. 122(21): p. 369-369.

226. Freedman, A., Neelapu, S. S., Nichols, C., Robertson, M. J., Djulbegovic, B., Winter, J. N., et.al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma, J Clin Oncol, 2009. 27(18): p. 3036-43., https://www.ncbi.nlm.nih.gov/pubmed/19414675

227. Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., et.al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma, J Clin Oncol, 2014. 32(17): p. 1797-803., https://www.ncbi.nlm.nih.gov/pubmed/24799467

228. Schuster, S. J., Neelapu, S. S., Gause, B. L., Janik, J. E., Muggia, F. M., Gockerman, J. P., et.al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma, J Clin Oncol, 2011. 29(20): p. 2787-94., https://www.ncbi.nlm.nih.gov/pubmed/21632504

229. Schaaf, M., Reiser, M., Borchmann, P., Engert, A., Skoetz, N., High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults, Cochrane Database Syst Rev, 2012. 1: p. CD007678., https://www.ncbi.nlm.nih.gov/pubmed/22258971

230. Lenz, G., Dreyling, M., Schiegnitz, E., Forstpointner, R., Wandt, H., Freund, M., et.al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group, Blood, 2004. 104(9): p. 2667-74., https://www.ncbi.nlm.nih.gov/pubmed/15238420

231. Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P., Haioun, C., et.al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA), Blood, 2006. 108(8): p. 2540-4., https://www.ncbi.nlm.nih.gov/pubmed/16835383

232. Bermudez, G., Gonzalez de Villambrosia, S., Martinez-Lopez, A., Batlle, A., Revert-Arce, J. B., Cereceda Company, L., et.al. Incidental and Isolated Follicular Lymphoma In Situ and Mantle Cell Lymphoma In Situ Lack Clinical Significance, Am J Surg Pathol, 2016. 40(7): p. 943-9., https://www.ncbi.nlm.nih.gov/pubmed/26945339

233. Jegalian, A. G., Eberle, F. C., Pack, S. D., Mirvis, M., Raffeld, M., Pittaluga, S., et.al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma, Blood, 2011. 118(11): p. 2976-84., https://www.ncbi.nlm.nih.gov/pubmed/21768298

234. Koch, K., Hoster, E., Ziepert, M., Unterhalt, M., Ott, G., Rosenwald, A., et.al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL, Ann Oncol, 2016. 27(7): p. 1323-9., https://www.ncbi.nlm.nih.gov/pubmed/27117536

235. Yuan, J., Greiner, T. C., Fu, K., Smith, L. M., Aoun, P., Chan, W. C., et.al. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy, Clin Lymphoma Myeloma Leuk, 2017. 17(8): p. 488-497 e2., https://www.ncbi.nlm.nih.gov/pubmed/28842137

236. Wahlin, B. E., Yri, O. E., Kimby, E., Holte, H., Delabie, J., Smeland, E. B., et.al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times, Br J Haematol, 2012. 156(2): p. 225-33., https://www.ncbi.nlm.nih.gov/pubmed/22126847

237. Martinelli, G., Ryan, G., Seymour, J. F., Nassi, L., Steffanoni, S., Alietti, A., et.al. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group, Ann Oncol, 2009. 20(12): p. 1993-9., https://www.ncbi.nlm.nih.gov/pubmed/19570964

238. Bacon, C. M., Diss, T. C., Ye, H., Liu, H., Goatly, A., Hamoudi, R., et.al. Follicular lymphoma of the thyroid gland, Am J Surg Pathol, 2009. 33(1): p. 22-34., https://www.ncbi.nlm.nih.gov/pubmed/18830125

239. Rasmussen, P. K., Ralfkiaer, E., Prause, J. U., Sjo, L. D., Specht, L., Rossing, H. H., et.al. Follicular lymphoma of the ocular adnexal region: a nation-based study, Acta Ophthalmol, 2015. 93(2): p. 184-91., https://www.ncbi.nlm.nih.gov/pubmed/25125069

240. Goodlad, J. R., MacPherson, S., Jackson, R., Batstone, P., White, J., Scotland, et.al. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites, Histopathology, 2004. 44(3): p. 268-76., https://www.ncbi.nlm.nih.gov/pubmed/14987231

241. Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, et.al. S2k - Leitlinie - Kutane Lymphome Update 2016, 2017., https://www.awmf.org/leitlinien/detail/ll/032-027.html

242. Konig, L., Stade, R., Rieber, J., Debus, J., Herfarth, K., Radiotherapy of indolent orbital lymphomas : Two radiation concepts, Strahlenther Onkol, 2016. 192(6): p. 414-21., https://www.ncbi.nlm.nih.gov/pubmed/27160291

243. Konig, L., Horner-Rieber, J., Bernhardt, D., Hommertgen, A., Rieken, S., Debus, J., et.al. Response rates and recurrence patterns after low-dose radiotherapy with 4Gy in patients with low-grade lymphomas, Strahlenther Onkol, 2018. 194(5): p. 454-461., https://www.ncbi.nlm.nih.gov/pubmed/29450588

244. Fasola, C. E., Jones, J. C., Huang, D. D., Le, Q. T., Hoppe, R. T., Donaldson, S. S., Low-dose radiation therapy (2 Gy x 2) in the treatment of orbital lymphoma, Int J Radiat Oncol Biol Phys, 2013. 86(5): p. 930-5., https://www.ncbi.nlm.nih.gov/pubmed/23726002

245. Yoshino, T., Miyake, K., Ichimura, K., Mannami, T., Ohara, N., Hamazaki, S., et.al. Increased incidence of follicular lymphoma in the duodenum, Am J Surg Pathol, 2000. 24(5): p. 688-93., https://www.ncbi.nlm.nih.gov/pubmed/10800987

246. Harada, A., Oguchi, M., Terui, Y., Takeuchi, K., Igarashi, M., Kozuka, T., et.al. Radiation therapy for localized duodenal low-grade follicular lymphoma, J Radiat Res, 2016. 57(4): p. 412-7., https://www.ncbi.nlm.nih.gov/pubmed/27009323

247. Schmatz, A. I., Streubel, B., Kretschmer-Chott, E., Puspok, A., Jager, U., Mannhalter, C., et.al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases, J Clin Oncol, 2011. 29(11): p. 1445-51., https://www.ncbi.nlm.nih.gov/pubmed/21383289

248. Shia, J., Teruya-Feldstein, J., Pan, D., Hegde, A., Klimstra, D. S., Chaganti, R. S., et.al. Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases, Am J Surg Pathol, 2002. 26(2): p. 216-24., https://www.ncbi.nlm.nih.gov/pubmed/11812943

249. Damaj, G., Verkarre, V., Delmer, A., Solal-Celigny, P., Yakoub-Agha, I., Cellier, C., et.al. Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review, Ann Oncol, 2003. 14(4): p. 623-9., https://www.ncbi.nlm.nih.gov/pubmed/12649111

250. Mori, M., Kobayashi, Y., Maeshima, A. M., Gotoda, T., Oda, I., Kagami, Y., et.al. The indolent course and high incidence of t(14;18) in primary duodenal follicular lymphoma, Ann Oncol, 2010. 21(7): p. 1500-5., https://www.ncbi.nlm.nih.gov/pubmed/20022910

251. Mirza, I., Macpherson, N., Paproski, S., Gascoyne, R. D., Yang, B., Finn, W. G., et.al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features, J Clin Oncol, 2002. 20(3): p. 647-55., https://www.ncbi.nlm.nih.gov/pubmed/11821444

252. Senff, N. J., Hoefnagel, J. J., Jansen, P. M., Vermeer, M. H., van Baarlen, J., Blokx, W. A., et.al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers, J Clin Oncol, 2007. 25(12): p. 1581-7., https://www.ncbi.nlm.nih.gov/pubmed/17353548

253. Zinzani, P. L., Quaglino, P., Pimpinelli, N., Berti, E., Baliva, G., Rupoli, S., et.al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas, J Clin Oncol, 2006. 24(9): p. 1376-82., https://www.ncbi.nlm.nih.gov/pubmed/16492713

254. Senff, N. J., Hoefnagel, J. J., Neelis, K. J., Vermeer, M. H., Noordijk, E. M., Willemze, R., et.al. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification, Arch Dermatol, 2007. 143(12): p. 1520-6., https://www.ncbi.nlm.nih.gov/pubmed/18087001

255. Brandenburg, A., Humme, D., Terhorst, D., Gellrich, S., Sterry, W., Beyer, M., Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas, Br J Dermatol, 2013. 169(5): p. 1126-32., https://www.ncbi.nlm.nih.gov/pubmed/23796422

256. Liu, Q., Salaverria, I., Pittaluga, S., Jegalian, A. G., Xi, L., Siebert, R., et.al. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma, Am J Surg Pathol, 2013. 37(3): p. 333-43., https://www.ncbi.nlm.nih.gov/pubmed/23108024

257. Louissaint, A., Jr., Schafernak, K. T., Geyer, J. T., Kovach, A. E., Ghandi, M., Gratzinger, D., et.al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations, Blood, 2016. 128(8): p. 1093-100., https://www.ncbi.nlm.nih.gov/pubmed/27325104

258. Attarbaschi, A., Beishuizen, A., Mann, G., Rosolen, A., Mori, T., Uyttebroeck, A., et.al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "Watch and wait" strategy after complete resection, Ann Hematol, 2013. 92(11): p. 1537-41., https://www.ncbi.nlm.nih.gov/pubmed/23665980

259. Link, B. K., Maurer, M. J., Nowakowski, G. S., Ansell, S. M., Macon, W. R., Syrbu, S. I., et.al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource, J Clin Oncol, 2013. 31(26): p. 3272-8., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757293/pdf/zlj3272.pdf

260. Wagner-Johnston, N. D., Link, B. K., Byrtek, M., Dawson, K. L., Hainsworth, J., Flowers, C. R., et.al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS), Blood, 2015. 126(7): p. 851-7., https://www.ncbi.nlm.nih.gov/pubmed/26105149

261. Sarkozy, C., Trneny, M., Xerri, L., Wickham, N., Feugier, P., Leppa, S., et.al. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial, J Clin Oncol, 2016. 34(22): p. 2575-82., https://www.ncbi.nlm.nih.gov/pubmed/27298402

262. Federico, M., Caballero Barrigon, M. D., Marcheselli, L., Tarantino, V., Manni, M., Sarkozy, C., et.al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis, Lancet Haematol, 2018. 5(8): p. e359-e367., https://www.ncbi.nlm.nih.gov/pubmed/30078408

263. Gleeson, M., Hawkes, E. A., Peckitt, C., Wotherspoon, A., Attygalle, A., Sharma, B., et.al. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013, Leuk Lymphoma, 2017. 58(8): p. 1805-1813., https://www.ncbi.nlm.nih.gov/pubmed/27931133

264. Lerch, K., Meyer, A. H., Stroux, A., Hirt, C., Keller, U., Viardot, A., et.al. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis, Ann Hematol, 2015. 94(6): p. 981-8., https://www.ncbi.nlm.nih.gov/pubmed/25645656

265. Villa, D., Crump, M., Panzarella, T., Savage, K. J., Toze, C. L., Stewart, D. A., et.al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group, J Clin Oncol, 2013. 31(9): p. 1164-71., https://www.ncbi.nlm.nih.gov/pubmed/23401459

266. Ban-Hoefen, M., Vanderplas, A., Crosby-Thompson, A. L., Abel, G. A., Czuczman, M. S., Gordon, L. I., et.al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database, Br J Haematol, 2013. 163(4): p. 487-95., https://www.ncbi.nlm.nih.gov/pubmed/24111533

267. Villa, D., Crump, M., Keating, A., Panzarella, T., Feng, B., Kuruvilla, J., Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation, Ann Oncol, 2013. 24(6): p. 1603-9., https://www.ncbi.nlm.nih.gov/pubmed/23425946

268. Robert-Koch-Institut, Zentrum für Krebsregisterdaten (ZfKD) des Robert Koch Instituts, 2016.

269. Goede, V., et al., Goede, V., et al., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions, N Engl J Med, 2014. 370: p. 1101 - 10., https://www.nejm.org/doi/full/10.1056/NEJMoa1313984

270. Fischer, K., et al., Fischer, K., et al., Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions, 2019. 380: p. 2225 - 2236.

271. Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., et.al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma, N Engl J Med, 2014. 370(11): p. 1008-18., https://www.ncbi.nlm.nih.gov/pubmed/24450858

272. Friedberg, J. W., Taylor, M. D., Cerhan, J. R., Flowers, C. R., Dillon, H., Farber, C. M., et.al. Follicular lymphoma in the United States: first report of the national LymphoCare study, J Clin Oncol, 2009. 27(8): p. 1202-8., https://www.ncbi.nlm.nih.gov/pubmed/19204203

273. Hiddemann, W., Cheson, B. D., How we manage follicular lymphoma, Leukemia, 2014. 28(7): p. 1388-95., https://www.ncbi.nlm.nih.gov/pubmed/24577532

274. Bastion, Y., Sebban, C., Berger, F., Felman, P., Salles, G., Dumontet, C., et.al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients, J Clin Oncol, 1997. 15(4): p. 1587-94., https://www.ncbi.nlm.nih.gov/pubmed/9193357

275. Maurer, M. J., Bachy, E., Ghesquieres, H., Ansell, S. M., Nowakowski, G. S., Thompson, C. A., et.al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma, Am J Hematol, 2016. 91(11): p. 1096-1101., https://www.ncbi.nlm.nih.gov/pubmed/27465588

276. Casulo, Carla, Le-Rademacher, Jennifer, Dixon, Jesse, Salles, Gilles, Hoster, Eva, Herold, Michael, et.al. Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials, Blood, 2017. 130(Suppl 1): p. 412-412.

277. Jurinovic, V., Metzner, B., Pfreundschuh, M., Schmitz, N., Wandt, H., Keller, U., et.al. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group, Biol Blood Marrow Transplant, 2018. 24(6): p. 1172-1179., https://www.ncbi.nlm.nih.gov/pubmed/29605716

278. Rummel, M. J., Al-Batran, S. E., Kim, S. Z., Welslau, M., Hecker, R., Kofahl-Krause, D., et.al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma, J Clin Oncol, 2005. 23(15): p. 3383-9., https://www.ncbi.nlm.nih.gov/pubmed/15908650

279. Matsumoto, K., Takayama, N., Aisa, Y., Ueno, H., Hagihara, M., Watanabe, K., et.al. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study, Int J Hematol, 2015. 101(6): p. 554-62.

280. Weide, R., Feiten, S., Friesenhahn, V., Heymanns, J., Kleboth, K., Thomalla, J., et.al. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions, Leuk Lymphoma, 2013. 54(8): p. 1640-6., https://www.ncbi.nlm.nih.gov/pubmed/23151046

281. Morschhauser, F., Mounier, N., Sebban, C., Brice, P., Solal-Celigny, P., Tilly, H., et.al. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS), Cancer, 2010. 116(18): p. 4299-308.

282. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A., Metzner, B., et.al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, 2004. 104(10): p. 3064-71., https://www.ncbi.nlm.nih.gov/pubmed/15284112

283. Sacchi, S., Marcheselli, L., Bari, A., Marcheselli, R., Pozzi, S., Luminari, S., et.al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study, Haematologica, 2008. 93(3): p. 398-404., https://www.ncbi.nlm.nih.gov/pubmed/18268277

284. Sehn, L. H., Chua, N., Mayer, J., Dueck, G., Trneny, M., Bouabdallah, K., et.al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial, Lancet Oncology, 2016. 17(8): p. 1081-93.

285. Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., et.al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment, J Clin Oncol, 2000. 18(17): p. 3135-43., https://www.ncbi.nlm.nih.gov/pubmed/10963642

286. Sehn, L. H., Goy, A., Offner, F. C., Martinelli, G., Caballero, M. D., Gadeberg, O., et.al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study, J Clin Oncol, 2015. 33(30): p. 3467-74., https://www.ncbi.nlm.nih.gov/pubmed/26282650

287. Tobinai, K., Igarashi, T., Itoh, K., Kurosawa, M., Nagai, H., Hiraoka, A., et.al. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study, Cancer Sci, 2011. 102(9): p. 1698-705., https://www.ncbi.nlm.nih.gov/pubmed/21645173

288. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., et.al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, J Clin Oncol, 2002. 20(10): p. 2453-63., https://www.ncbi.nlm.nih.gov/pubmed/12011122

289. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., et.al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma, J Clin Oncol, 2002. 20(15): p. 3262-9., https://www.ncbi.nlm.nih.gov/pubmed/12149300

290. Salles, G., Schuster, S. J., de Vos, S., Wagner-Johnston, N. D., Viardot, A., Blum, K. A., et.al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study, Haematologica, 2017. 102(4): p. e156-e159., https://www.ncbi.nlm.nih.gov/pubmed/27979923

291. Eyre, T. A., Osborne, W. L., Gallop-Evans, E., Ardeshna, K. M., Kassam, S., Sadullah, S., et.al. Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma, Br J Haematol, 2018. 181(4): p. 555-559., https://www.ncbi.nlm.nih.gov/pubmed/28342183

292. Witzig, T. E., Wiernik, P. H., Moore, T., Reeder, C., Cole, C., Justice, G., et.al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma, J Clin Oncol, 2009. 27(32): p. 5404-9., https://www.ncbi.nlm.nih.gov/pubmed/19805688

293. Leonard, J. P., Jung, S. H., Johnson, J., Pitcher, B. N., Bartlett, N. L., Blum, K. A., et.al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance), J Clin Oncol, 2015. 33(31): p. 3635-40., https://www.ncbi.nlm.nih.gov/pubmed/26304886

294. Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., et.al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma, J Clin Oncol, 2019. p. JCO1900010., https://www.ncbi.nlm.nih.gov/pubmed/30897038

295. Andorsky, David J, Cataruozolo, Patricia E, Mouro, Jorge L, Li, Ju, Fustier, P., Foon, Kenneth A., et.al. Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL)., J Clin Oncol, 2017. 35(suppl; abstr 7502):

296. Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., et.al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma, Ann Oncol, 2017. 28(9): p. 2169-2178., https://www.ncbi.nlm.nih.gov/pubmed/28633365

297. Zinzani, P., Wagner-Johnston, N., Miller, C., Ardeshna, K., Tertreault, S., Assouline, S., et.al. DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA, Hematological Oncology, 2017. 35(S2): p. 69-70., https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2437_57

298. Gopal, A. K., Schuster, S. J., Fowler, N. H., Trotman, J., Hess, G., Hou, J. Z., et.al. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study, J Clin Oncol, 2018. 36(23): p. 2405-2412., https://www.ncbi.nlm.nih.gov/pubmed/29851546

299. Bartlett, N. L., Costello, B. A., LaPlant, B. R., Ansell, S. M., Kuruvilla, J. G., Reeder, C. B., et.al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial, Blood, 2018. 131(2): p. 182-190., https://www.ncbi.nlm.nih.gov/pubmed/29074501

300. Fowler, Nathan, Nastoupil, Loretta, de Vos, Sven, Knapp, Mark, Flinn, Ian W., Chen, Robert W, et.al. Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study, Blood, 2016. 128(22): p. 1804-1804.

301. Davids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G., et.al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, J Clin Oncol, 2017. 35(8): p. 826-833., https://www.ncbi.nlm.nih.gov/pubmed/28095146

302. Swinnen, L.J., Flowers, C.R., Wang, D., Reid, E., Fowler, N., Cordero, J., et.al. VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY, Hematological Oncology, 2017. 35(S2): p. 90-90., https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2437_78

303. Zinzani, Pier Luigi, Topp, Max S, Yuen, Sam LS, Rusconi, Chiara, Fleury, Isabelle, Pro, Barbara, et.al. Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data, Blood, 2016. 128(22): p. 617-617.

304. Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., et.al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study, Journal of Clinical Oncology, 2016. 34(23): p. 2698-704.

305. Nastoupil, L.J., Westin, J., Fowler, N., Fanale, M., Samaniego, F., Oki, Y., et.al. HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN-LABEL, PHASE II STUDY, Hematological Oncology, 2017. 35(S2): p. 120-121., https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2437_108

306. van Oers, M. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., et.al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial, Blood, 2006. 108(10): p. 3295-301., https://www.ncbi.nlm.nih.gov/pubmed/16873669

307. van Oers, M. H., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., et.al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study, J Clin Oncol, 2010. 28(17): p. 2853-8., https://www.ncbi.nlm.nih.gov/pubmed/20439641

308. Ghielmini, M., Schmitz, S. F., Cogliatti, S. B., Pichert, G., Hummerjohann, J., Waltzer, U., et.al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule, Blood, 2004. 103(12): p. 4416-23., https://www.ncbi.nlm.nih.gov/pubmed/14976046

309. Vidal, L., Gafter-Gvili, A., Salles, G., Dreyling, M. H., Ghielmini, M., Hsu Schmitz, S. F., et.al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials, J Natl Cancer Inst, 2011. 103(23): p. 1799-806., https://www.ncbi.nlm.nih.gov/pubmed/22021664

310. Yahalom, J., Radiotherapy of follicular lymphoma: updated role and new rules, Curr Treat Options Oncol, 2014. 15(2): p. 262-8., https://www.ncbi.nlm.nih.gov/pubmed/24700284

311. Yahalom, J., Illidge, T., Specht, L., Hoppe, R. T., Li, Y. X., Tsang, R., et.al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group, Int J Radiat Oncol Biol Phys, 2015. 92(1): p. 11-31., https://www.ncbi.nlm.nih.gov/pubmed/25863750

312. Haas, R. L., Poortmans, P., de Jong, D., Aleman, B. M., Dewit, L. G., Verheij, M., et.al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas, J Clin Oncol, 2003. 21(13): p. 2474-80., https://www.ncbi.nlm.nih.gov/pubmed/12829665

313. Schmidberger, H., Hey-Koch, S., Strahlentherapie bei Non-Hodgin-Lymphomen, Der Onkologe, 2015. 21(10): p. 913-924., https://doi.org/10.1007/s00761-015-2964-7

314. Schouten, H. C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnsen, H. E., et.al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial, J Clin Oncol, 2003. 21(21): p. 3918-27., https://www.ncbi.nlm.nih.gov/pubmed/14517188

315. Sebban, C., Brice, P., Delarue, R., Haioun, C., Souleau, B., Mounier, N., et.al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study, J Clin Oncol, 2008. 26(21): p. 3614-20., https://www.ncbi.nlm.nih.gov/pubmed/18559872

316. Le Gouill, S., De Guibert, S., Planche, L., Brice, P., Dupuis, J., Cartron, G., et.al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study, Haematologica, 2011. 96(8): p. 1128-35., https://www.ncbi.nlm.nih.gov/pubmed/21486862

317. Evens, A. M., Vanderplas, A., LaCasce, A. S., Crosby, A. L., Nademanee, A. P., Kaminski, M. S., et.al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project, Cancer, 2013. 119(20): p. 3662-71., https://www.ncbi.nlm.nih.gov/pubmed/23921646

318. Casulo, C., Friedberg, J. W., Ahn, K. W., Flowers, C., DiGilio, A., Smith, S. M., et.al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis, Biol Blood Marrow Transplant, 2017., https://www.ncbi.nlm.nih.gov/pubmed/29242111

319. Jimenez-Ubieto, A., Grande, C., Caballero, D., Yanez, L., Novelli, S., Hernandez, M. T., et.al. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma, Cancer Med, 2017. 6(12): p. 2766-2774., https://www.ncbi.nlm.nih.gov/pubmed/29076254

320. Montoto, S., Corradini, P., Dreyling, M., Ghielmini, M., Kimby, E., Lopez-Guillermo, A., et.al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party, Haematologica, 2013. 98(7): p. 1014-21., https://www.ncbi.nlm.nih.gov/pubmed/23813647

321. Casulo, C., Friedberg, J. W., Ahn, K. W., Flowers, C., DiGilio, A., Smith, S. M., et.al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis, Biol Blood Marrow Transplant, 2018. 24(6): p. 1163-1171., https://www.ncbi.nlm.nih.gov/pubmed/29242111

322. Pettengell, R., Schmitz, N., Gisselbrecht, C., Smith, G., Patton, W. N., Metzner, B., et.al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation, J Clin Oncol, 2013. 31(13): p. 1624-30., https://www.ncbi.nlm.nih.gov/pubmed/23547078

323. Rohatiner, A. Z., Nadler, L., Davies, A. J., Apostolidis, J., Neuberg, D., Matthews, J., et.al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up, J Clin Oncol, 2007. 25(18): p. 2554-9., https://www.ncbi.nlm.nih.gov/pubmed/17515573

324. Kornacker, M., Stumm, J., Pott, C., Dietrich, S., Sussmilch, S., Hensel, M., et.al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up, Ann Oncol, 2009. 20(4): p. 722-8., https://www.ncbi.nlm.nih.gov/pubmed/19179546

325. Metzner, B., Pott, C., Muller, T. H., Gebauer, W., Casper, J., Kraemer, D., et.al. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation, Ann Oncol, 2013. 24(6): p. 1609-15., https://www.ncbi.nlm.nih.gov/pubmed/23393125

326. Pettengell, R., Uddin, R., Boumendil, A., Robinson, S.P., Smith, G., Hawkins, T., et.al. DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL, Hematological Oncology, 2017. 35(S2): p. 32-33., https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2437_13

327. Montoto, S., Canals, C., Rohatiner, A. Z., Taghipour, G., Sureda, A., Schmitz, N., et.al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study, Leukemia, 2007. 21(11): p. 2324-31., https://www.ncbi.nlm.nih.gov/pubmed/17637813

328. El-Najjar, I., Boumendil, A., Luan, J. J., Bouabdallah, R., Thomson, K., Mohty, M., et.al. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party, Ann Oncol, 2014. 25(11): p. 2224-9., https://www.ncbi.nlm.nih.gov/pubmed/25193988

329. Bento, L., Boumendil, A., Finel, H., Le Gouill, S., Amorim, S., Monjanel, H., et.al. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party, Bone Marrow Transplant, 2017. 52(8): p. 1120-1125., https://www.ncbi.nlm.nih.gov/pubmed/28530668

330. Robinson, S. P., Canals, C., Luang, J. J., Tilly, H., Crawley, C., Cahn, J. Y., et.al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT, Bone Marrow Transplant, 2013. 48(11): p. 1409-14., https://www.ncbi.nlm.nih.gov/pubmed/23771004

331. Urbano-Ispizua, A., Pavletic, S. Z., Flowers, M. E., Klein, J. P., Zhang, M. J., Carreras, J., et.al. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen, Biol Blood Marrow Transplant, 2015. 21(10): p. 1746-53., https://www.ncbi.nlm.nih.gov/pubmed/25981509

332. Sureda, A., Zhang, M. J., Dreger, P., Carreras, J., Fenske, T., Finel, H., et.al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR, Cancer, 2018. 124(8): p. 1733-1742., https://www.ncbi.nlm.nih.gov/pubmed/29424927

333. Robinson, S. P., Boumendil, A., Finel, H., Schouten, H., Ehninger, G., Maertens, J., et.al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT, Ann Oncol, 2016., https://www.ncbi.nlm.nih.gov/pubmed/26961149

334. Hari, P., Carreras, J., Zhang, M. J., Gale, R. P., Bolwell, B. J., Bredeson, C. N., et.al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning, Biol Blood Marrow Transplant, 2008. 14(2): p. 236-45., https://www.ncbi.nlm.nih.gov/pubmed/18215784

335. Heinzelmann, F., Bethge, W., Beelen, D. W., Engelhard, M., Kroger, N., Dreger, P., et.al. Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas, Bone Marrow Transplant, 2016. 51(5): p. 654-62., https://www.ncbi.nlm.nih.gov/pubmed/26855152

336. Hamadani, M., Horowitz, M. M., Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?, J Oncol Pract, 2017. 13(12): p. 798-806., https://www.ncbi.nlm.nih.gov/pubmed/29232542

337. Epperla, N., Ahn, K. W., Armand, P., Jaglowski, S., Ahmed, S., Kenkre, V. P., et.al. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma, Biol Blood Marrow Transplant, 2018. 24(1): p. 78-85., https://www.ncbi.nlm.nih.gov/pubmed/29032272

338. Laport, G. G., Wu, J., Logan, B., Bachanova, V., Hosing, C., Fenske, T., et.al. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network, Biol Blood Marrow Transplant, 2016. 22(8): p. 1440-1448., https://www.ncbi.nlm.nih.gov/pubmed/27118571

339. Corradini, P., Dodero, A., Farina, L., Fanin, R., Patriarca, F., Miceli, R., et.al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome, Leukemia, 2007. 21(11): p. 2316-23., https://www.ncbi.nlm.nih.gov/pubmed/17597807

340. Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., et.al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma, J Clin Oncol, 2008. 26(2): p. 211-7., https://www.ncbi.nlm.nih.gov/pubmed/18056679

341. Delgado, J., Canals, C., Attal, M., Thomson, K., Campos, A., Martino, R., et.al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma, Leukemia, 2011. 25(3): p. 551-5., https://www.ncbi.nlm.nih.gov/pubmed/21183951

342. Thomson, K. J., Morris, E. C., Milligan, D., Parker, A. N., Hunter, A. E., Cook, G., et.al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma, J Clin Oncol, 2010. 28(23): p. 3695-700., https://www.ncbi.nlm.nih.gov/pubmed/20606089

343. Mandigers, C. M., Raemaekers, J. M., Schattenberg, A. V., Roovers, E. A., Bogman, M. J., van der Maazen, R. W., et.al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma, Br J Haematol, 1998. 100(1): p. 198-206., https://www.ncbi.nlm.nih.gov/pubmed/9450812

344. Pidala, J., Anasetti, C., Jim, H., Quality of life after allogeneic hematopoietic cell transplantation, Blood, 2009. 114(1): p. 7-19., https://www.ncbi.nlm.nih.gov/pubmed/19336756

345. Cornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhauser, M., Juliusson, G., et.al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach, Nat Rev Clin Oncol, 2012. 9(10): p. 579-90., https://www.ncbi.nlm.nih.gov/pubmed/22949046

346. Kahl, B. S., Follicular lymphoma: are we ready for a risk-adapted approach?, Hematology Am Soc Hematol Educ Program, 2017. 2017(1): p. 358-364., https://www.ncbi.nlm.nih.gov/pubmed/29222279

347. Sureda, A., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., et.al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015, Bone Marrow Transplant, 2015. 50(8): p. 1037-56.

348. Raimondi, R., Tosetto, A., Oneto, R., Cavazzina, R., Rodeghiero, F., Bacigalupo, A., et.al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study, Blood, 2012. 120(6): p. 1327-33., https://www.ncbi.nlm.nih.gov/pubmed/22740454

349. McClune, B. L., Ahn, K. W., Wang, H. L., Antin, J. H., Artz, A. S., Cahn, J. Y., et.al. Allotransplantation for patients age >/=40 years with non-Hodgkin lymphoma: encouraging progression-free survival, Biol Blood Marrow Transplant, 2014. 20(7): p. 960-8., https://www.ncbi.nlm.nih.gov/pubmed/24641829

350. Müller, CR, Mytilineos, J., Ottinger, H., Arnold, R., Bader, P., Beelen, D., Deutscher Konsensus 2013 zur immungenetischen Spenderauswahl für die allogene Stammzelltransplantation., 2013., http://www.dag-kbt.de

351. Tomblyn, M. R., Ewell, M., Bredeson, C., Kahl, B. S., Goodman, S. A., Horowitz, M. M., et.al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response, Biol Blood Marrow Transplant, 2011. 17(7): p. 1051-7., https://www.ncbi.nlm.nih.gov/pubmed/21073974

352. Burchert, A., Muller, M. C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., et.al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia, J Clin Oncol, 2010. 28(8): p. 1429-35., https://www.ncbi.nlm.nih.gov/pubmed/20142590

353. Howard, C. A., Fernandez-Vina, M. A., Appelbaum, F. R., Confer, D. L., Devine, S. M., Horowitz, M. M., et.al. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), Biol Blood Marrow Transplant, 2015. 21(1): p. 4-7., https://www.ncbi.nlm.nih.gov/pubmed/25278457

354. Kanate, A. S., Mussetti, A., Kharfan-Dabaja, M. A., Ahn, K. W., DiGilio, A., Beitinjaneh, A., et.al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors, Blood, 2016. 127(7): p. 938-47., https://www.ncbi.nlm.nih.gov/pubmed/26670632

355. Dietrich, S., Finel, H., Martinez, C., Tischer, J., Blaise, D., Chevallier, P., et.al. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation, Leukemia, 2016. 30(10): p. 2086-2089., https://www.ncbi.nlm.nih.gov/pubmed/27146790

356. Ghosh, N., Karmali, R., Rocha, V., Ahn, K. W., DiGilio, A., Hari, P. N., et.al. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis, J Clin Oncol, 2016. 34(26): p. 3141-9., https://www.ncbi.nlm.nih.gov/pubmed/27269951

357. Oh, Y. K., Ha, C. S., Samuels, B. I., Cabanillas, F., Hess, M. A., Cox, J. D., Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies, Radiology, 1999. 210(2): p. 483-6., https://www.ncbi.nlm.nih.gov/pubmed/10207433

358. Truong, Q., Shah, N., Knestrick, M., Curley, B., Hu, Y., Craig, M., et.al. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission, Clin Lymphoma Myeloma Leuk, 2014. 14(1): p. 50-5., https://www.ncbi.nlm.nih.gov/pubmed/24119465

359. Lin, T. L., Kuo, M. C., Shih, L. Y., Dunn, P., Wang, P. N., Wu, J. H., et.al. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas, Ann Hematol, 2012. 91(11): p. 1741-5., https://www.ncbi.nlm.nih.gov/pubmed/22729139

360. Sussman, J., Varela, N. P., Cheung, M., Hicks, L., Kraftcheck, D., Mandel, J., et.al. Follow-up care for survivors of lymphoma who have received curative-intent treatment, Curr Oncol, 2016. 23(5): p. e499-e513., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081023/pdf/conc-23-e499.pdf

361. Smith-Bindman, R., Lipson, J., Marcus, R., Kim, K. P., Mahesh, M., Gould, R., et.al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer, Arch Intern Med, 2009. 169(22): p. 2078-86., https://www.ncbi.nlm.nih.gov/pubmed/20008690

362. Brix, G., Lechel, U., Glatting, G., Ziegler, S. I., Munzing, W., Muller, S. P., et.al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations, J Nucl Med, 2005. 46(4): p. 608-13., https://www.ncbi.nlm.nih.gov/pubmed/15809483

363. Kwee, T. C., Kwee, R. M., Nievelstein, R. A., Imaging in staging of malignant lymphoma: a systematic review, Blood, 2008. 111(2): p. 504-16., https://www.ncbi.nlm.nih.gov/pubmed/17916746

364. Semelka, R. C., Armao, D. M., Elias, J., Jr., Huda, W., Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI, J Magn Reson Imaging, 2007. 25(5): p. 900-9., https://www.ncbi.nlm.nih.gov/pubmed/17457809

365. Morton, L. M., Curtis, R. E., Linet, M. S., Bluhm, E. C., Tucker, M. A., Caporaso, N., et.al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype, J Clin Oncol, 2010. 28(33): p. 4935-44., https://www.ncbi.nlm.nih.gov/pubmed/20940199

366. Giri, S., Bhatt, V. R., Verma, V., Pathak, R., Bociek, R. G., Vose, J. M., et.al. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study, Clin Lymphoma Myeloma Leuk, 2017. 17(9): p. 569-574., https://www.ncbi.nlm.nih.gov/pubmed/28709798

367. Beiggi, S., Johnston, J. B., Seftel, M. D., Pitz, M. W., Kumar, R., Banerji, V., et.al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study, Br J Cancer, 2013. 109(5): p. 1287-90., https://www.ncbi.nlm.nih.gov/pubmed/23860531

368. Berg, J. W., The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma, J Natl Cancer Inst, 1967. 38(5): p. 741-52., https://www.ncbi.nlm.nih.gov/pubmed/5229351

369. Greene, M. H., Hoover, R. N., Fraumeni, J. F., Jr., Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism, J Natl Cancer Inst, 1978. 61(2): p. 337-40., https://www.ncbi.nlm.nih.gov/pubmed/277720

370. Tashima, C. K., Association of malignant melanoma and malignant lymphoma, Lancet, 1973. 2(7823): p. 266., https://www.ncbi.nlm.nih.gov/pubmed/4124459

371. Herr, M. M., Schonfeld, S. J., Dores, G. M., Withrow, D. R., Tucker, M. A., Curtis, R. E., et.al. Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival, J Natl Cancer Inst, 2018., https://www.ncbi.nlm.nih.gov/pubmed/29659938

372. Martin, P., Chen, Z., Cheson, B. D., Robinson, K. S., Williams, M., Rajguru, S. A., et.al. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma, Br J Haematol, 2017. 178(2): p. 250-256., https://www.ncbi.nlm.nih.gov/pubmed/28419413

373. Magnano, L., Montoto, S., Gonzalez-Barca, E., Briones, J., Sancho, J. M., Muntanola, A., et.al. Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial, Ann Hematol, 2017. 96(4): p. 639-646., https://www.ncbi.nlm.nih.gov/pubmed/28101592

374. Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., et.al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 2011. 13(1): p. 1-10., https://www.ncbi.nlm.nih.gov/pubmed/21169385

375. Valcovici, M., Andrica, F., Serban, C., Dragan, S., Cardiotoxicity of anthracycline therapy: current perspectives, Arch Med Sci, 2016. 12(2): p. 428-35., https://www.ncbi.nlm.nih.gov/pubmed/27186191

376. Moser, E. C., Noordijk, E. M., van Leeuwen, F. E., le Cessie, S., Baars, J. W., Thomas, J., et.al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma, Blood, 2006. 107(7): p. 2912-9., https://www.ncbi.nlm.nih.gov/pubmed/16339404

377. Armenian, S. H., Mertens, L., Slorach, C., Venkataraman, K., Mascarenhas, K., Nathwani, N., et.al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma, Cancer, 2018. 124(4): p. 850-857., https://www.ncbi.nlm.nih.gov/pubmed/29112235

378. Salz, T., Zabor, E. C., de Nully Brown, P., Dalton, S. O., Raghunathan, N. J., Matasar, M. J., et.al. Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors, J Clin Oncol, 2017. 35(34): p. 3837-3843., https://www.ncbi.nlm.nih.gov/pubmed/28922087

379. Smith, S. K., Mayer, D. K., Zimmerman, S., Williams, C. S., Benecha, H., Ganz, P. A., et.al. Quality of life among long-term survivors of non-Hodgkin lymphoma: a follow-up study, J Clin Oncol, 2013. 31(2): p. 272-9., https://www.ncbi.nlm.nih.gov/pubmed/23213093

380. Mehnert, A., Employment and work-related issues in cancer survivors, Crit Rev Oncol Hematol, 2011. 77(2): p. 109-30., https://www.ncbi.nlm.nih.gov/pubmed/20117019

381. Ellis, G., Gardner, M., Tsiachristas, A., Langhorne, P., Burke, O., Harwood, R. H., et.al. Comprehensive geriatric assessment for older adults admitted to hospital, Cochrane Database Syst Rev, 2017. 9: p. CD006211., https://www.ncbi.nlm.nih.gov/pubmed/28898390

382. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Supportive Therapie bei onkologischen PatientInnen - Langversion 1.1, 2017, AWMF Registernummer: 032/054OL, 2017., http://leitlinienprogramm-onkologie.de/Supportive-Therapie.95.0.html

383. Ärzteschaft, Arzneimittelkommission der deutschen, Schwere Immundefekte nach Behandlung mit Rituximab, Deutsches Ärzteblatt, 2018. 115(49):

384. Klippstein, A., Schneider, C. P., Sayer, H. G., Hoffken, K., Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer, J Cancer Res Clin Oncol, 2003. 129(5): p. 316-9., https://www.ncbi.nlm.nih.gov/pubmed/12756557

385. Carter, S. J., Bernstein, S. H., Friedberg, J. W., Barr, P. M., Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma, Leuk Res, 2011. 35(11): p. e223-4., https://www.ncbi.nlm.nih.gov/pubmed/21824654

386. Brugger, W., Ghielmini, M., Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management, Oncologist, 2013. 18(8): p. 954-64., https://www.ncbi.nlm.nih.gov/pubmed/23900001

387. Rieger, C. T., Liss, B., Mellinghoff, S., Buchheidt, D., Cornely, O. A., Egerer, G., et.al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO), Ann Oncol, 2018. 29(6): p. 1354-1365., https://www.ncbi.nlm.nih.gov/pubmed/29688266

388. Sandherr, M., Hentrich, M., von Lilienfeld-Toal, M., Massenkeil, G., Neumann, S., Penack, O., et.al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO), Ann Hematol, 2015. 94(9): p. 1441-50.

389. Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., et.al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis, CA Cancer J Clin, 2013. 63(6): p. 419-37., https://www.ncbi.nlm.nih.gov/pubmed/24590861

390. Oerlemans, S., Mols, F., Issa, D. E., Pruijt, J. H., Peters, W. G., Lybeert, M., et.al. A high level of fatigue among long-term survivors of non-Hodgkin's lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands, Haematologica, 2013. 98(3): p. 479-86., https://www.ncbi.nlm.nih.gov/pubmed/22929981

391. Oerlemans, S., Issa, D. E., van den Broek, E. C., Nijziel, M. R., Coebergh, J. W., Mols, F., et.al. Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: results of the population-based PHAROS-registry, Eur J Haematol, 2014. 93(3): p. 229-38., https://www.ncbi.nlm.nih.gov/pubmed/24702126

392. Mustian, K. M., Alfano, C. M., Heckler, C., Kleckner, A. S., Kleckner, I. R., Leach, C. R., et.al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis, JAMA Oncol, 2017. 3(7): p. 961-968., https://www.ncbi.nlm.nih.gov/pubmed/28253393

393. Knips, L., Bergenthal, N., Streckmann, F., Monsef, I., Elter, T., Skoetz, N., Aerobic physical exercise for adult patients with haematological malignancies, Cochrane Database Syst Rev, 2019. 1: p. CD009075., https://www.ncbi.nlm.nih.gov/pubmed/30702150

394. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten, Langversion 2.0, 2018; AWMF Registernummer: 018/029 OL, 2018., http://www.leitlinienprogramm-onkologie.de/leitlinien/hodgkin-lymphom/

395. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Lang-version 2.01 (Konsultationsfassung) AWMF-Registernummer: 128/001OL, 2019., https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/

396. Noseck-Licul, Michaela, Erhebung traditioneller und komplementärer Heilmethoden in ÖsterreichDokumentationszentrum für traditionelle und komplementäre Heilmethoden in Österreich, Projektbericht, 2011., http://www.cam-tm.com/Jacomo/upload/projektbericht.pdf

397. Fennell, D., Liberato, A. S., Zsembik, B., Definitions and patterns of CAM use by the lay public, Complement Ther Med, 2009. 17(2): p. 71-7., https://www.ncbi.nlm.nih.gov/pubmed/19185264

398. Deng, G. E., Frenkel, M., Cohen, L., Cassileth, B. R., Abrams, D. I., Capodice, J. L., et.al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals, J Soc Integr Oncol, 2009. 7(3): p. 85-120., https://www.ncbi.nlm.nih.gov/pubmed/19706235

399. Jütte, Robert, Geschichte der alternativen Medizin. Von der Volksmedizin zu den unkonventionellen Therapien von heuteC.H. Beck, 1996. 1:

400. Frenkel, M., Cohen, L., Effective communication about the use of complementary and integrative medicine in cancer care, J Altern Complement Med, 2014. 20(1): p. 12-8., https://www.ncbi.nlm.nih.gov/pubmed/23863085

401. Blodt, S., Mittring, N., Schutzler, L., Fischer, F., Holmberg, C., Horneber, M., et.al. A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study, BMC Cancer, 2016. 16(1): p. 843., https://www.ncbi.nlm.nih.gov/pubmed/27809814

402. Horneber, M., van Ackeren, G., Fischer, F., Kappauf, H., Birkmann, J., Addressing Unmet Information Needs: Results of a Clinician-Led Consultation Service About Complementary and Alternative Medicine for Cancer Patients and Their Relatives, Integr Cancer Ther, 2018. 17(4): p. 1172-1182., https://www.ncbi.nlm.nih.gov/pubmed/30352519

403. Shanafelt, T. D., Bowen, D. A., Venkat, C., Slager, S. L., Zent, C. S., Kay, N. E., et.al. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia, Leuk Res, 2009. 33(2): p. 263-70., https://www.ncbi.nlm.nih.gov/pubmed/18656259

404. Ben-Arye, E., Schiff, E., Golan, O., Ethical issues in integrative oncology, Hematol Oncol Clin North Am, 2008. 22(4): p. 737-53, x., https://www.ncbi.nlm.nih.gov/pubmed/18638699

405. Weiger, W. A., Smith, M., Boon, H., Richardson, M. A., Kaptchuk, T. J., Eisenberg, D. M., Advising patients who seek complementary and alternative medical therapies for cancer, Ann Intern Med, 2002. 137(11): p. 889-903., https://www.ncbi.nlm.nih.gov/pubmed/12458989

406. Cassileth, B. R., Berlyne, D., Counseling the cancer patient who wants to try unorthodox or questionable therapies, Oncology (Williston Park), 1989. 3(4): p. 29-33; discussion 34, 40-1., https://www.ncbi.nlm.nih.gov/pubmed/2701416

407. Davis, E. L., Oh, B., Butow, P. N., Mullan, B. A., Clarke, S., Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review, Oncologist, 2012. 17(11): p. 1475-81., https://www.ncbi.nlm.nih.gov/pubmed/22933591

408. Schofield, P., Diggens, J., Charleson, C., Marigliani, R., Jefford, M., Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians, Patient Educ Couns, 2010. 79(2): p. 143-51., https://www.ncbi.nlm.nih.gov/pubmed/19783116

409. Tasaki, K., Maskarinec, G., Shumay, D. M., Tatsumura, Y., Kakai, H., Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives, Psychooncology, 2002. 11(3): p. 212-20., https://www.ncbi.nlm.nih.gov/pubmed/12112481

410. Montbriand, M. J., Abandoning biomedicine for alternate therapies: oncology patients' stories, Cancer Nurs, 1998. 21(1): p. 36-45., https://www.ncbi.nlm.nih.gov/pubmed/9494229

411. Rausch Osian, S., Leal, A. D., Allmer, C., Maurer, M. J., Nowakowski, G., Inwards, D. J., et.al. Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors, Leuk Lymphoma, 2015. 56(2): p. 434-9.

412. Hamilton, A. S., Miller, M. F., Arora, N. K., Bellizzi, K. M., Rowland, J. H., Predictors of use of complementary and alternative medicine by non-hodgkin lymphoma survivors and relationship to quality of life, Integr Cancer Ther, 2013. 12(3): p. 225-35., https://www.ncbi.nlm.nih.gov/pubmed/22791309

413. Habermann, T. M., Thompson, C. A., LaPlant, B. R., Bauer, B. A., Janney, C. A., Clark, M. M., et.al. Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study, Am J Hematol, 2009. 84(12): p. 795-8., https://www.ncbi.nlm.nih.gov/pubmed/19894247

414. Ben-Arye, E., Attias, S., Tadmor, T., Schiff, E., Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions, Leuk Lymphoma, 2010. 51(8): p. 1414-23., https://www.ncbi.nlm.nih.gov/pubmed/20528250

415. Mishra, R., Sharma, S., Sharma, R. S., Singh, S., Sardesai, M. M., Sharma, S., et.al. Viscum articulatum Burm. f. aqueous extract exerts antiproliferative effect and induces cell cycle arrest and apoptosis in leukemia cells, J Ethnopharmacol, 2018. 219: p. 91-102., https://www.ncbi.nlm.nih.gov/pubmed/29555410

416. Kovacs, E., Kuehn, J. J., Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters?, Biomed Pharmacother, 2002. 56(3): p. 152-8., https://www.ncbi.nlm.nih.gov/pubmed/12046687

417. Pryme, I. F., Bardocz, S., Pusztai, A., Ewen, S. W., Pfuller, U., A mistletoe lectin (ML-1)-containing diet reduces the viability of a murine non-Hodgkin lymphoma tumor, Cancer Detect Prev, 2004. 28(1): p. 52-6., https://www.ncbi.nlm.nih.gov/pubmed/15041078

418. Gorter, R. W., Joller, P., Stoss, M., Cytokine release of a keratinocyte model after incubation with two different Viscum album L extracts, Am J Ther, 2003. 10(1): p. 40-7., https://www.ncbi.nlm.nih.gov/pubmed/12522519

419. Hallek, M., Interleukin-6-mediated cell growth in multiple myeloma--a role for Viscum album extracts?, Onkologie, 2005. 28(8-9): p. 387.

420. Hugo, F., Dittmar, T., Treutler, E. K., Zanker, K. S., Kuehn, J. J., The Viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's Lymphoma cell lines, Onkologie, 2005. 28(8-9): p. 415-20., https://www.ncbi.nlm.nih.gov/pubmed/16160404

421. Hagenah, W., Dorges, I., Gafumbegete, E., Wagner, T., [Subcutaneous manifestations of a centrocytic non-Hodgkin lymphoma at the injection site of a mistletoe preparation], Dtsch Med Wochenschr, 1998. 123(34-35): p. 1001-4., https://www.ncbi.nlm.nih.gov/pubmed/9739765

422. Kameda, G., Kempf, W., Oschlies, I., Michael, K., Seifert, G., Langler, A., Nodal anaplastic large-cell lymphoma ALK-1- with CD30+ cutaneous lymphoproliferation treated with mistletoe: spontaneous remission or treatment response?, Klin Padiatr, 2011. 223(6): p. 364-7., https://www.ncbi.nlm.nih.gov/pubmed/22052633

423. Orange, M., Lace, A., Fonseca, M. P., von Laue, B. H., Geider, S., Kienle, G. S., Durable Regression of Primary Cutaneous B-Cell Lymphoma Following Fever-inducing Mistletoe Treatment: Two Case Reports, Glob Adv Health Med, 2012. 1(1): p. 18-25., https://www.ncbi.nlm.nih.gov/pubmed/24278797

424. Pierach, C. A., [Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non hodgkin lymphoma], Dtsch Med Wochenschr, 2000. 125(31-32): p. 958-60., https://www.ncbi.nlm.nih.gov/pubmed/10967963

425. Stumpf, C., Rosenberger, A., Rieger, S., Troger, W., Schietzel, M., [Mistletoe extracts in the therapy of malignant, hematological and lymphatic diseases--a monocentric, retrospective analysis over 16 years], Forsch Komplementarmed Klass Naturheilkd, 2000. 7(3): p. 139-46., https://www.ncbi.nlm.nih.gov/pubmed/10899748

426. Sammons, H. M., Gubarev, M. I., Krepkova, L. V., Bortnikova, V. V., Corrick, F., Job, K. M., et.al. Herbal medicines: challenges in the modern world. Part 2. European Union and Russia, Expert Rev Clin Pharmacol, 2016. 9(8): p. 1117-27., https://www.ncbi.nlm.nih.gov/pubmed/27171366

427. Arends, J., Bertz, H., Bischoff, S. C., Fietkau, R., Herrmann, H. J., Holm, E., et.al. S3-Leitline der Deutschen Gesellschaft für Ern ährungsmedizin e. V. (DGEM) in Kooperation mit der Deutschen Gesellschaft für Hämatologie und Onkologie e. V. (DGHO), der Arbeitsgemeinschaft „Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin“ der Deutschen Krebsgesellschaft (ASORS) und der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE), Aktuel Ernahrungsmed, 2015. 40(05): p. e1-e74.

428. Paul, C., Ernährung und Krebs - Was kann die Diätberatung leisten?, Aktuel Ernahrungsmed, 2001. 26(04): p. 153-159.

429. Russell, N. C., Hoelscher, D. M., Lowenstein, N., Patients previously treated for lymphoma consume inadequate or excessive amounts of five key nutrients, J Soc Integr Oncol, 2007. 5(3): p. 118-24., https://www.ncbi.nlm.nih.gov/pubmed/17761131

430. Kelly, J. L., Salles, G., Goldman, B., Fisher, R. I., Brice, P., Press, O., et.al. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies, J Clin Oncol, 2015. 33(13): p. 1482-90., https://www.ncbi.nlm.nih.gov/pubmed/25823738

431. Tracy, S. I., Maurer, M. J., Witzig, T. E., Drake, M. T., Ansell, S. M., Nowakowski, G. S., et.al. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma, Blood Cancer J, 2017. 7(8): p. e595., https://www.ncbi.nlm.nih.gov/pubmed/28841207

432. Pludowski, P., Holick, M. F., Grant, W. B., Konstantynowicz, J., Mascarenhas, M. R., Haq, A., et.al. Vitamin D supplementation guidelines, J Steroid Biochem Mol Biol, 2018. 175: p. 125-135., https://www.ncbi.nlm.nih.gov/pubmed/28216084

433. German Nutrition, Society, New reference values for vitamin D, Ann Nutr Metab, 2012. 60(4): p. 241-6., https://www.ncbi.nlm.nih.gov/pubmed/22677925

434. Bischoff-Ferrari, Heike Annette, Vitamin-D-Supplementation in der Praxis, Schweiz Med Forum, 2014. p. 949-953.

435. Keum, N., Lee, D. H., Greenwood, D. C., Manson, J. E., Giovannucci, E., Vitamin D Supplements and Total Cancer Incidence and Mortality: a Meta-analysis of randomized controlled trials, Ann Oncol, 2019., https://www.ncbi.nlm.nih.gov/pubmed/30796437

436. (ÄZQ), Ärztliches Zentrum für Qualität in der Medizin, E, Gramsch, JD, Hoppe, G, Jonitz, A, Köhler, al., Ollenschläger G et, Kompendium Q-M-A. Qualitätsmanagement in der ambulanten VersorgungDt. Ärzte-Verl., 2008.

437. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Manual Qualitätsindikatoren. Manual für Autoren., 2009. äzq Schriftenreihe: 36:, http://www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe36.pdf

438. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe (DKH), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)), Entwicklung von Leitlinien basierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie. Version 2.0. 2017., 2017., http://leitlinienprogramm-onkologie.de/Informationen-zur-Methodik.53.0.html

439. Weinstock, D. M., Dalla-Favera, R., Gascoyne, R. D., Leonard, J. P., Levy, R., Lossos, I. S., et.al. A roadmap for discovery and translation in lymphoma, Blood, 2015. 125(13): p. 2175-7., https://www.ncbi.nlm.nih.gov/pubmed/25814490

440. Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., et.al. The European Hematology Association Roadmap for European Hematology Research: a consensus document, Haematologica, 2016. 101(2): p. 115-208., https://www.ncbi.nlm.nih.gov/pubmed/26819058